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of chronic obstructive pulmonary disease (COPD). 
 
By Simon Charles Bourne 
 
COPD (Chronic Obstructive Pulmonary Disease) worldwide has a prevalence of 
10% in men and 8.5% in women. Exacerbations of COPD account for 
approximately 10% of all acute medical admissions. Projected prevalence 
figures suggest that by 2020 COPD will be the third leading cause of mortality 
worldwide thus imposing a significant burden on healthcare resources in the 
future. Acute exacerbations are not only responsible for a decline in the 
patient’s quality of life, but have a major socioeconomic impact. Following a 
pilot study that showed current smokers recover lung function much more 
slowly from their exacerbation than ex smokers, I initiated a properly powered 
prospective study to investigate the difference between the two groups. 
  A total of 58 patients admitted with acute infectious exacerbations of COPD 
were recruited to the study to determine the effect of smoking status on their 
exacerbation. Throughout the admission lung function was measured. Sputum 
was cultured for bacteria, and PCR used to detect viral infection. Blood and 
sputum cells were analyzed by flow cytometry. Serum was collected for CRP 
levels. 
  Ex-smokers recovered significantly more quickly than current smokers in all 
spirometric parameters (P<0.01), and were discharged sooner (mean 3.08 vs 
5.59 days, P<0.001). Sputum culture was positive for more pathogenic bacteria 
in current smokers, especially H. influenzae, which was associated with a 
significantly higher CRP rise (p<0.05) than any other organism. CD8+ T cells 
predominated in the sputum of ex-smokers while CD4+ T cells were the 
dominant cell type in current smokers (p<0.01).  
  Current smoking is a risk factor for more severe exacerbations, delayed 
recovery and prolonged hospitalization. This may result from a variety of factors 
including bacterial, immune mediated responses and systemic inflammation. 
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Background 
 
 
The idea for this research project was the result of an investigation of patients 
recovering  from  acute  exacerbations  of  COPD  who  were  severe  enough  to 
need admission to hospital. This pilot study was performed in Poole Hospital in 
Dorset in 2002. I monitored the recovery of patients during their hospital stay by 
performing  daily  pulmonary  function  testing until  they  were  discharged from 
hospital. I analyzed the results of these investigations and found that in terms of 
improvement  in  FEV1  and  FVC  the  ex-smokers  (defined  as  more  than  one 
year’s  abstinence  from  smoking)  recovered  much  more  quickly  from  their 
exacerbations  than  current  smokers.  This  finding  was  presented  at  the 
European Respiratory Society Meeting in Stockholm in 2002. (2) 
   
The  results  of  this  study  were  presented  to  the  respiratory  department  at 
Southampton University Hospitals Trust. From this meeting a draft protocol was 
agreed to find the cause of the differences between the two groups, other than 
of course their smoking status.  
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Acute Exacerbations of COPD 
 
 
Chapter 1 Introduction 
 
1.1 Introduction and definitions 
The average patient with Chronic Obstructive Pulmonary Disease (COPD) will 
have between 1-3 exacerbations per year. These exacerbations account for at 
least 50% of the treatment cost and have a very high mortality. Mortality from 
acute exacerbations is on the rise in the U.K. and also in America (3), 
especially in the female and elderly population. This year in the U.K. alone, 
COPD will have been responsible for the premature death of 30,000 people (4). 
   
A recent audit from the Royal College of Physicians (RCOP) has highlighted the 
potentially serious problems for COPD services in the U.K. The audit was the 
first ever comprehensive national audit of COPD admissions. The project was 
undertaken by the RCOP and the British Thoracic Society (BTS) between the 
years 2003 and 2004.  234 hospitals in the U.K. took part in the audit, which 
was aimed at finding ways of improving the quality of care. This was the first 
time an audit of this type has covered the whole of the U.K.  (5) The audit is 
currently being repeated in 2008, the results will be released later this year. 
This audit and resulting press release from the college received widespread 
publicity in the popular and medical press, both of which have called for an 
increase in funding in respiratory services. They report that COPD is the fifth 
most common cause of death in England and Wales, and is predicted to rise to 
the third leading cause worldwide by 2020. (6)  
   
The prevalence of COPD in the community has been estimated as anywhere 
between 2-18%. The lower estimations come mainly from GP surgery database 
studies; in the United Kingdom prevalence studies based on actual spirometry 
put the figure at about 10%, rising with increasing age. (7-11) COPD accounts 
for up to 10% of all acute admissions, which makes it a priority area for all 
hospitals concerned with effective management of acute medical admissions   16
(5, 12). More than one in ten patients with COPD admitted to hospital are dead 
within 90 days of admission, and over 1 in 3 are readmitted to hospital during 
that time (5).  The risk of exacerbations and hospitalisation is related to FEV1; 
30% of severe exacerbations admitted to hospital are in those with an 
FEV1<30%. This was observed in the 2 recent large cohort exacerbation 
studies – the TORCH and INSPIRE studies. (13, 14) Studies on mortality after 
hospitalization for an acute exacerbation of COPD have shown a one-year 
mortality ranging from 22% to 43%, and a 2-year mortality of 36 to 49%. A 
cohort study looking at mortality after hospital admission has recently been 
published. This study recruited 416 patients who were followed up for 24 
months. During the follow up 122 (29.3%) of the 416 patients died. Patients with 
concurrent diabetes had the highest increased mortality rate. Other risk factors 
were advanced age, low FEV1 and lower health status. Current smokers in this 
study had a relative risk of 1.73 of dying from their COPD, compared to ex-
smokers. Patients treated with inhaled corticosteroids and/or long-acting beta-2 
agonists had a lower risk of death than patients using neither of these types of 
treatment (15). Risk factors identified in other studies are increasing age, a 
higher CO2, long-term use of oral corticosteroids, reduced health status, marital 
status, depression, co-morbidity and prior hospital admission (16, 17). 
 
It has been shown that median recovery times are 6 days for PEFR (Peak 
Expiratory Flow Rate) and 7 days for daily total symptom score; but the 
recovery of PEFR to baseline values can take much longer (30-90 days). It has 
also been shown that symptom changes during an exacerbation do not closely 
reflect those of lung function. (18) 
 
To date, the only proven cost-effective therapies for COPD are the cessation or 
prevention of smoking, which is the single most common cause of COPD, and 
vaccination to prevent influenza and pneumococcal infection. Combination 
inhalers of corticosteroids and long acting beta agonists, (13) and long acting 
anticholinergics (19) reduce exacerbation burden and hospital admissions (13, 
20, 21), this is important because hospitalisation and associated costs 
represent the greatest healthcare expenditures for people with the disease.  
 
Long-term oxygen therapy is also among the most costly interventions in terms 
of total money spent on direct medical costs for COPD treatment, although it is 
probably cost-effective because of its positive impact on rates of mortality. (22)   17
In fact, oxygen therapy is the only intervention to date that has been shown to 
decrease death rates due to COPD, although the use of a combination inhaler 
containing flixotide and salmeterol in the TOwards a Revolution in COPD health 
(TORCH) study came close to showing a significant impact on mortality in those 
with an FEV1 < 60% (p=0.052).  The results of this study are backed up by the 
results from the INSPIRE (Investigating New Standards for Prophylaxis in 
Reduction of Exacerbations) study which showed a reduction in mortality 
versus tiotropium, although this was an additional endpoint. (23) Similarly, 
pulmonary rehabilitation programmes appear to benefit patients in terms of 
quality of life; however, long-term cost-effectiveness and effects on mortality 
have yet to be elucidated. (24) 
 
COPD is a major cause of morbidity worldwide and affects 14 million patients in 
the United States alone.  (25).  The total economic cost of COPD in the US in 
1993 was estimated to be over $15.5 billion, with $6.1 billion for hospitalisation, 
$4.4 billion for physician and other fees, $2.5 billion for drugs, $1.5 billion for 
nursing home care and $1.0 billion for home care. (26) Currently there are no 
diagnostic tests to define if a patient is suffering from an acute exacerbation, or 
to monitor their progress following treatment. However, several definitions have 
been made, these are discussed later. (27) 
 
COPD - The Disease 
COPD is a heterogeneous disease, with components of chronic bronchitis, 
emphysema, small airways disease, and perhaps in some patients certain 
features of asthma. (28) COPD is defined by the Global Initiative for Obstructive 
Lung Disease (GOLD) as a "disease state characterised by airflow limitation 
that is not fully reversible. …The airflow limitation is usually both progressive 
and associated with an abnormal inflammatory response of the lungs to noxious 
particles or gases".  
   
The absence of reversibility tends to exclude asthma by definition, although 
asthma can coexist with COPD, with asthma being a relatively common disease 
in the general population. The GOLD workshop report explicitly defines airflow 
limitation using simple spirometric indices. Specifically, airflow limitation is 
defined as an FEV1/forced vital capacity (FVC)<70% and a post bronchodilator 
FEV1<80% of predicted. A good quality test is a necessary precondition for 
adequate interpretation, but it is not sufficient. One significant unsolved problem   18
is that the interpretation of spirometry as "normal" or "abnormal" is based on 
comparisons with reference values derived from healthy persons. Lower limits 
of the healthy subject range (normal range) are treated as absolute 
demarcations of normal or abnormal. This is particularly problematic for COPD 
in that it is a condition defined by spirometry with no other independent means 
of making the diagnosis. The true sensitivity and specificity of current 
categorisations is unknown. 
 
COPD Pathogenesis 
The clinical impact of cigarette smoking, which ranges from negligible to end-
stage lung disease, is determined to some extent by individual susceptibility 
factors. (29) Understanding the factors that lead to emphysema is useful for 
predicting which individuals are at risk. α1 antitrypsin deficiency is one factor 
that results in a predisposition to smoking-induced emphysema, but despite 
intensive study, few other susceptibility factors are as well defined. (30) 
 
COPD is a more of a syndrome than a distinct disease; comprising a 
combination of emphysematous changes and chronic bronchitis of varying 
proportions within the lung parenchyma; combined with a systemic 
inflammatory response. The terms ‘pink puffer’ to denote the cachectic 
emphysematous patient with a barrel shaped hyperinflated chest and the ‘blue 
bloater’ describing the patient with chronic bronchitis with cyanosis and cor 
pulmonale are striking in their imagery, but represent the end stages of the 2 
extremes of the disease. We do come across such patients in our clinical 
practice but for the most part this patient group is heterogeneous. 
 
The key inflammatory cells involved in the pathogenesis of COPD are thought 
to be the CD8+ T cells and the neutrophil. (31) We do not fully understand what 
initiates this inflammatory and destructive process in certain individuals, but 
spares the majority with an extensive smoking history. 
 
There is also increasing interest in autoimmunity as the process that 
drives/initiates the disease; a recent paper has shown that emphysema is 
possibly an autoimmune disease characterized by the presence of antielastin 
antibodies and T-helper type 1 (TH1) responses, which correlate with 
emphysema severity. (32) 
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The central airways in COPD exhibit a sub epithelial infiltration of mononuclear 
cells, mucous gland hypertrophy and inflammation. In severe COPD there is 
also a sub epithelial infiltration of neutrophils. In the smaller peripheral airways 
there is pronounced goblet cell hyperplasia and sub epithelial infiltration of 
CD8+ T lymphocytes, smooth muscle hypertrophy, wall fibrosis, and destruction 
of the alveolar attachments. (33, 34) 
 
More details of the various cells and inflammatory mechanisms are provided 
under separate headings which focus on individual biomarkers of COPD. 
 
 
 
Definition of acute exacerbation of COPD 
 
Exacerbations of COPD are thought to be caused by interactions between host 
factors, bacteria, viruses, and changes in air quality to produce increased 
inflammation in the lower airway. Most do not take into account the role of co- 
morbidities in the symptomology.  
  
In 1987, Anthonisen and colleagues investigated whether antibiotic therapy 
could have a beneficial effect in the management of COPD exacerbations. (35) 
They defined exacerbations specifically in terms of increased dyspnoea, 
sputum production, and sputum purulence: signs indicative of an infectious 
aetiology. However, exacerbations of COPD comprise a range of symptoms, 
and the presence or absence of increased sputum production or purulence 
provides only part of the picture. In a study of exacerbations, some patients 
showing other hallmark signs of an exacerbation would be excluded by using 
this definition; which serves to demonstrate how an all-encompassing, 
standardized definition is essential to assess the impact of clinical research.  
 
Following the 1999 Aspen Lung Conference dedicated to COPD, a working 
group of respiratory physicians from the US and Europe was convened to 
discuss a common operational definition that could be presented to 
international health-care providers and all groups involved in respiratory care. 
The definition agreed was that an exacerbation of COPD is: 
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`a sustained worsening of the patient's condition, from the stable state and 
beyond normal day-to-day variations, that is acute in onset and necessitates a 
change in regular medication in a patient with underlying COPD`. (36). This 
definition has also been adopted in the latest GOLD Guideline. (37) 
When defining an exacerbation, it is necessary to pinpoint when the decline in 
any of the continuous measures is worse than expected, taking into account 
day-to-day variability (figure 1.1 below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  Day to day variability in FEV1 in a patient with COPD taken from 
(36) 
 
We must however be alert enough to take into account that other co-morbidities 
may play a role when a patient with COPD presents with an acute exacerbation 
e.g. heart failure. 
 
The working group also tried to further define an exacerbation according to 
respiratory and systemic symptoms and signs (table 1.1), and also to stage the 
exacerbation in terms of use of healthcare services (table 1.2). The problem 
with the use of health care utilization is the fact that it adds unpredictable 
variables to an already complex cocktail of pathological and physiological 
variables. 
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Table 1.1. Clinical descriptors used to characterize acute COPD exacerbations 
(36) 
 
 
 
Table 1.2. Staging of a COPD exacerbation – health care utilization (36) 
 
A staging system has also been devised by the East London COPD research 
group to take into account upper and lower airway symptoms. A patient is 
defined as having an exacerbation if the following symptom patterns are 
experienced for at least two consecutive days: either two or more of three major 
symptoms (increase in dyspnoea, sputum purulence or sputum volume) or any 
one major symptom together with any one of the flowing minor symptoms: 
increase in nasal discharge, wheeze, sore throat, cough or fever. (38) 
 
 
 
Category  Descriptor 
Respiratory  Increase shortness of breath 
  Increase volume and purulence of 
sputum 
  Increased Cough 
  Shallow rapid breathing 
Systemic  Increased body temperature 
  Tachycardia 
Severity  Level of health care utilization 
Mild  Increased need for medication, can manage at home 
Moderate  Increased need for medication, needs medical assistance 
Severe  Patient recognises rapid deterioration and requires 
hospitalisation   22
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Aetiologies of exacerbations of COPD (39) 
 
The common causes of exacerbations are presented in Figure 1.2, and will be 
discussed in more detail individually. 
 
A combination of these definitions is probably more useful than each one 
individually. For the purposes of my study I used the following definition 
‘An acute exacerbation of COPD is defined as a sustained worsening of the 
patient's condition which could be attributable to their COPD, from the stable 
state and beyond normal day-to-day variations, that is acute in onset and 
necessitates a change in regular medication in a patient with underlying COPD. 
It often presents with the combination of increasing dyspnoea, and an alteration 
in sputum production’.  
 
1.2 Spirometry 
At the heart of this study lies spirometry. Forced Expiratory Volume in one 
second (FEV1) is the most commonly employed measurement used in COPD. 
The tight link between FEV1 and COPD reflects the fact that spirometry is the 
standard for defining the presence of airway obstruction. (25, 37, 40) The 
progressive loss of FEV1, the physiological variable that characterises COPD 
severity also predicts mortality. 
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FEV1 is also used because of its consistency, reproducibility, and because it is 
also discriminatory. (37) The problem with analysing the research in this area is 
that FEV1 can be reported in many different ways: 
 
1.  As a percentage of baseline 
2.  As a percentage of predicted 
3.  In units of volume 
4.  As a percentage of achievable 
 
Many experts in the field do not recognise percentage change as being wholly 
clinically relevant, and prefer to see absolute change in millilitres (ml) recorded 
and charted. The natural average variability in FEV1 for patients with moderate 
COPD is approximately 160ml. 
 
There are also problems with measuring FEV1. COPD is a diverse disease 
primarily of the small airways and FEV1, besides being effort dependent, is not 
a very sensitive measure of small airways function. FEV1 also correlates very 
poorly with dyspnoea, quality of life and some other long-term outcome 
measures. (41) 
 
An often used measurement in respiratory physiology is Inspiratory Capacity 
(IC). Increases in IC and Vital Capacity (VC) reasonably reflect the lung volume 
response to a bronchodilator and can be used to infer the decrease in end-
expiratory lung volume. (42-45) 
 
IC can also measure the reduction in lung volume secondary to treatment; a 
higher IC infers a patient is able to perform spirometry from lung volumes lower 
than before treatment. Because the spirogram is performed at lower lung 
volumes, flow rates, being dependent on absolute lung volume, may not appear 
to be increased. (46) This can be inferred (rather than impractically measuring 
lung volumes) from an increase in their IC, due to a reduction in Functional 
Residual Capacity (FRC). 
 
Given the emerging physiological and clinical rationale for
 pharmacological 
lung-volume reduction, assessment of volume
 responses to bronchodilators is 
likely to be highly relevant
 in COPD. It has been shown that patients with COPD 
develop dynamic hyperinflation (DH), which contributes
 to dyspnoea and poor   24
exercise tolerance. (44) DH has been found to correlate well with more 
sophisticated measurements of lung volume, even during exercise. (47) IC has 
been found to predict functionality during exercise in patients with COPD, and is 
responsible for the blunting of the usual increase in tidal volume during 
exercise. (48) 
Progressive DH leads to an increasing sensation
 of breathlessness that makes 
an important contribution to the
 limitation of exercise in most patients with
 
COPD. In these patients
 changes in end-expiratory lung volume (EELV) 
constitute an important
 outcome in assessing the effects of therapeutic 
interventions
 on the development of dynamic hyperinflation during exercise.
 (48)
 
The assessment of dynamic changes in EELV is routinely carried
 out by serial 
IC manoeuvres assuming
 that, in patients with COPD, total lung capacity (TLC) 
does
 not change appreciably during exercise. 
There are a significant number of patients
 with COPD who do not develop 
progressive hyperinflation during exercise but
 still report dyspnoea as the main 
cause of exercise limitation.
 (48)
 The results reported for this category of COPD 
patients are,
 however, discrepant as EELV has either been reported to remain
 
constant with increasing intensity or actually to fall,
 as is commonly seen in 
healthy subjects. Accordingly, exercise
 limitation in these patients is not 
associated with end expiratory
 dynamic hyperinflation. This implies that simply 
tracking changes
 in EELV during exercise is not informative of all the factors
 
that intensify dyspnoea and reduce exercise capacity in these
 patients. (49) 
IC is determined by
 a slow manoeuvre (slow inspiration until maximum volume 
after
 regular tidal breathing) and is easy to measure with standard equipment 
available in any hospital and on some spirometers in general practice. Using 
standard spirometers the patient is asked to perform at least 3 tidal breathes 
before performing a full inspiratory manoeuvre, followed by a forced expiratory 
manoeuvre. Changes in IC from quiet breathing measured by the spirometer
 
show a good relationship with optoelectronic plethysmography during exercise 
and recovery. (49) 
 
Some studies have also shown an increase in IC after bronchodilator 
administration,
 which correlates closely with the improvement of dyspnoea 
sensation
 at rest. (50) Other studies have also shown that an improvement in IC   25
of 0.3l appears to correspond to a clinically meaningful improvement in 
dyspnoea scores and exercise tolerance. (42) The explanation for these 
findings is that lung deflation allows the patient to breathe at a lower, more 
comfortable lung volume, providing relief from dyspnoea. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Flow volume tracing in COPD – This figure shows changes are 
observed in inspiratory capacity after inhalation of a short acting β agonist; 
however no change in FEV1 is observed – improvements in symptoms may be 
secondary to a reduction in hyperinflation. Taken from reference (44) 
 
In a study by Pellegrino (44), one-third of patients with chronic airflow 
obstruction treated with salbutamol demonstrated a bronchodilator response 
based on FEV1. Two-thirds of the patients responded with changes in IC. Of the 
two, IC appears to be the best available choice. (figure 1.3). 
 
As may be expected by their infrequent use, IC and Peak Expiratory Flow 
(PEF) parameters involve some unresolved issues. Their measurement 
accuracy and precision are not well known and current pulmonary function 
testing guidelines do not yet address the details of their measurement.  
 
The last measurement is Forced Vital Capacity (FVC). FVC has to be carefully 
standardised, because in extremely well motivated patients it can be prolonged 
by as much as 20 seconds. (51) It is however one of the worst measurements 
in terms of reproducibility, with patients terminating their breath before a plateau 
is reached or being too unwell to perform a FVC manoeuvre. Forced Expiratory   26
Volume in six seconds (FEV6) has been found to be a good surrogate for FVC 
and in the healthy lung study FEV1/FEV6 was found to be equivalent to 
FEV1/FVC in predicting decline at 5 years. Reference equations based on the 
third National Health and Nutrition Examination Survey (NHANES III) study 
include both FEV1/FVC and FEV1/FEV6 ratios. (52). A study in 502 consecutive 
patients in Christchurch, New Zealand, demonstrated that the FEV1/FEV6 ratio 
performed as well as FEV1/FVC in diagnosing airflow obstruction. (51). The 
sensitivity and specificity of FEV1/FEV6 for obstruction defined by FEV1/FVC 
were 99.5 and 100%, respectively, after allowing for a possible 100 ml error in 
FEV1 and FEV6. The FEV6 was 25% less variable than FVC. 
 
1.3 Biomarkers in COPD 
A marker of an exacerbation has been the Holy Grail in chest medicine for a 
number of years. There are currently no specific diagnostic tests on sputum, 
blood, or airway biopsies that can be measured to tell us if a patient with COPD 
is having an exacerbation. However, this field has been extensively studied. 
 
For several years physicians have been using the Anthonisen definition of an 
infective exacerbation, (35) but we know that not all exacerbations conform to 
this definition. (38) Although
 it is presumed that exacerbations are associated 
with increased
 airway inflammation, as in patients with asthma, there is
 little 
information available on the nature of inflammatory markers
 at exacerbation, 
especially when studied close to the onset of symptoms. Concentrations
 of 
inflammatory cytokines in induced sputum have been shown to
 be increased in 
patients with COPD when stable,
 but changes
 in induced sputum at 
exacerbation have not been extensively studied. (53) It certainly has rarely 
been studied in patients admitted with their COPD exacerbation.  
 
Induced sputum has provided considerable information about the inflammatory 
process, including proximal airways but may not closely reflect distal 
inflammatory processes. (54) Exhaled gases and breath condensate are non-
invasive procedures, so repeated measurements are possible, but for some 
assays the variability is relatively high. (55) There is relatively little information 
about how any of these biomarkers relate to other clinical outcomes, such as 
progression of the disease, severity of disease, clinical subtypes, or response 
to therapy. More information is also needed about the variability in these 
measurements. In the future, pulmonary biomarkers may be useful in predicting   27
disease progression, indicating disease instability, and in predicting response to 
current therapies and novel therapies, many of which are now in development. 
(54) 
 
Only sputum neutrophils, (54) and IL-8, (56, 57) as well as serum TNFα, (56) 
and C-reactive protein (CRP), (58) show any trend toward separating different 
stages of COPD. In some studies changes in inflammatory markers have been 
associated with the type of infection at exacerbation. In a study of 30 patients 
admitted with their COPD, patients with bacterial growth in their sputum had 
significantly higher levels of MPO and IL-8 in sputum compared to patients with 
evidence of a viral insult. (59) 
 
Even
 among non-current smokers there is good evidence for low grade 
systemic
 inflammation in those with chronic airflow limitation. This
 suggests 
that, once COPD develops, cessation of smoking may
 not fully attenuate the 
inflammatory process associated with
 this condition. (60, 61) 
 
Secretary leukoproteinase inhibitor (SLPI) is the main proteinase inhibitor found 
in the larger airways and submucosal glands and also has antiviral and 
antibacterial properties (62). During the stable clinical state the level of SLPI in 
the sputum has been found to be significantly lower in patients with frequent 
exacerbations (three or more exacerbations in the preceding 12 months) than in 
those with infrequent exacerbations. (63) 
 
CRP is raised in most studies of patients with exacerbations of COPD, however 
the standardised CRP usually used in hospitals is not always sensitive enough, 
therefore, most studies rely on high sensitivity assays that give results of 
hsCRP. (60) CRP has also been shown to be linked to worse pulmonary 
function even in those subjects with no pulmonary disease, in a large cohort of 
`healthy subjects` those with FEV1 falling in the lowest quartile was associated 
with a non attributable rise in CRP. (64) In the last couple of years there has 
been an explosion of papers linking COPD with CRP. The relationship between 
ventilatory function and markers of systemic inflammation, such as CRP, is 
affected by several factors that are associated with subclinical systemic 
inflammation, including smoking, obesity, and reduced cardiorespiratory fitness. 
(65)  
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CRP is an acute-phase protein produced by the liver in response to IL-6 
stimulation. CRP is raised in most conditions associated with infection, 
inflammation, or tissue damage, for which it is a sensitive marker. It has also 
been shown in a recent large study of 90 patients looking for biomarkers of 
acute COPD to be the most sensitive indicator of exacerbation, along with 
MPIF-1 and IL-6, its predictive value is increased significantly when used 
alongside symptom scores. (58) (figure 1.4) In this study there were no 
significant relationships between biomarker concentrations and clinical indices 
of exacerbation severity. 
 
The most commonly studied biomarkers in plasma and sputum are endothelin 1 
levels, IL6, IL8, TNF-α and its soluble receptors sTNF-R55 and –R75, CRP, 
and fibrinogen. The problem with these measurements is that they require a 
certain degree of technical expertise that is not present in all hospitals. 
 
 
 
 
Figure 1.4: from  Hurst, J. R.(2006). ‘Use of Plasma Biomarkers at 
Exacerbation of Chronic Obstructive Pulmonary Disease’ (58). Plasma CRP is 
as good as IL6 and other more difficult to measure cytokines during an 
exacerbation. 
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1. IL-6/IL-8 
IL-6 is produced
 by airway macrophages and bronchial epithelium, while IL-8 is
 
largely produced by neutrophils and macrophages. Correlations
 examined in 
stable sputum samples suggest that those patients
 with a longer history of 
smoking have higher IL-6 levels. (53). In the same study there was no 
relationship between cytokine
 levels and the current smoking status, and 
exacerbation frequency was found to be correlated with stable IL-6 levels, and 
IL-8 levels. (figure 1.5). The median IL-6
 level was significantly higher at the 
time of an exacerbation than during stable conditions. The differences in IL-8 
levels and the cell counts between exacerbation
 and baseline values did not 
reach statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Comparison of sputum IL-6 and IL-8 levels according to 
exacerbation frequency. From (53) 
 
 
The total
 cell count, neutrophil count, and macrophage count in the sputum
, 
have not always been shown to be increased in patients with more frequent 
exacerbations. This suggests that increased IL-6 and IL-8 expression in the
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sputum may be due to increased cytokine production by the bronchial
 
epithelium.  
 
IL-8 levels are related to cell counts,
 both neutrophils and macrophages, (38) 
but it is likely that a component
 of the increased sputum IL-8 level in patients 
with frequent exacerbations
 is produced by bronchial epithelial cells. It is likely
 
that the increase in IL-6 levels during an exacerbation might
 partly be due to 
production by the epithelial cells, and is
 not necessarily proportional to the rise 
in total non-squamous cell count. There
 is debate as to the exact role of the 
interaction between the
 airway cells, and bacteria as an inflammatory stimulus 
in COPD. Some studies have observed that IL-6 is produced
 in response to H. 
influenzae endotoxin. (66)  
 
Levels of IL-8 are related to the sputum
 neutrophil and total cell counts, (38) 
suggesting that neutrophil recruitment
 is a major source of IL-8 during an 
exacerbation. The observation that plasma fibrinogen levels are also associated 
with increased rates of hospital admission with exacerbation, as well as with 
reduced lung function and risk of COPD (67), may support a role for IL-6 which 
is the primary cytokine regulating fibrinogen expression.  
 
2. TNFα 
TNF-α has been described as being loosely correlated with resting energy 
expenditure and weight loss in COPD. (68) Interleukin-8, but not TNFα, was 
found to be significantly higher in the COPD patients when compared to 
asthmatics. (69)  
 
An additional study has suggested that monocytes from underweight patients 
with COPD produce increased amounts of TNF-α in response to endotoxin 
challenge. (70) In this context, TNF-α may contribute to the muscle weakness, 
muscle loss, and cachexia, which limit exercise performance.  
 
Unfortunately a recent clinical study has also failed to demonstrate a clinical 
effect of anti-TNF α antibody (infliximab) in patients with moderate to severe 
COPD. (71) 
 
3. Endothelin 1    31
Endothelin-1 (ET-1) is a potent vasoconstrictive and bronchoconstrictive 
peptide that has been implicated in the pathophysiology
 of asthma. (72). It is 
thought to have important pro-inflammatory effects
 in the airways, being both a 
chemoattractant and an upregulator
 of other inflammatory mediators such as 
the IL-6
 and IL-8. (73) There are several sites of ET-1 production within
 the 
human lung, including the bronchial epithelium, pulmonary endothelium,
 and 
alveolar macrophages. Rises in both plasma and sputum ET-1 levels have 
been
 found during exacerbations, with the sputum showing relatively
 larger 
changes. (74) 
 
4. Fibrinogen 
The mature fibrinogen molecule is composed of three pairs of polypeptide 
chains: two α chains, two β chains, and two γ chains. In vitro functional studies 
have shown that synthesis of the β chain is rate-limiting. Fibrinogen is 
expressed by the liver and levels can increase in response to intense acute 
phase stimuli such as trauma, surgery, or strenuous exercise, and fibrinogen 
levels are chronically elevated in the presence of mild inflammatory stimuli such 
as smoking. IL6 is the main mediator of acute phase-induced fibrinogen 
synthesis, and sequences responsive to IL6 are present in the promoter regions 
of the genes coding for the three fibrinogen chains. (75) Fibrinogen levels rise 
non-specifically and are a general measure of inflammation. 
 
There also seems to be a relationship between the changes in fibrinogen, and 
IL-6 levels in stable COPD patients. Analysis of data in stable COPD patients 
has revealed significantly greater rises in fibrinogen when exacerbations were 
associated with purulent sputum, increased cough, and symptomatic colds. 
(76). A meta-analysis has found than fibrinogen levels are higher in COPD 
patients when compared to controls (60). Data from Dahl et al (67) suggest that
 
individuals with increased systemic inflammatory markers such
 as fibrinogen 
experience an accelerated decline in lung function
 and are at increased risk of 
COPD hospitalisations in the future. (67) Moreover, during periods of 
exacerbation,
 plasma levels of fibrinogen and serum levels of IL-6 increase
 
significantly. This may further contribute to increased cardiovascular
 morbidity, 
and mortality in patients with COPD. (76) 
 
There is now a large body of evidence to indicate
 that systemic inflammation is 
present in patients with stable
 COPD. This finding may explain, at least in part,   32
the high prevalence
 of systemic complications such as cachexia, osteoporosis, 
and
 cardiovascular diseases among patients with COPD. Future studies
 are 
needed to determine whether attenuation of the systemic
 inflammatory process 
can modify the risk of these complications
 in COPD.  
 
 
 
 
5. Bronchial Biopsies  
Although the inflammation in COPD involves predominately lung parenchyma 
and small airways (bronchioles), (77, 78) bronchial biopsies reflect the cellular 
abnormalities seen in the peripheral lung (33, 79). Bronchial biopsies have 
been useful for documenting the structural changes, cellular patterns, and 
expression of inflammatory proteins in patients with COPD. In stable COPD, 
there is increased infiltration of macrophages and activated T lymphocytes, 
particularly of CD8 T lymphocytes (79), which express IFN-γ, CXCL10 (IFN-γ 
inducible 10-kD protein (IP-10), and IL-9. (80) Moreover, these lymphocytes 
express chemokine receptors associated with a Th1 type response, such as 
CXCR3, in contrast to lymphocytes in asthma which express chemokine 
receptors typical of a Th2 type response (CCR4). (81) . Although a prominent 
neutrophilia is present in the airway lumen of patients with stable COPD, it is 
not observed at the tissue level, except in patients with severe airflow limitation. 
(82) Finally, during exacerbations of the disease, an increased recruitment of 
eosinophils and neutrophils has been described, which is associated with 
upregulation of specific chemoattractants, such as CCL5, and CXCL5 (epithelial 
neutrophil-activating peptide-78). (83) There is also a reduction in histone 
deacetylase (HDAC) activity and HDAC2 expression in bronchial biopsies of 
patients with COPD compared with normal smokers and nonsmokers, and this 
is correlated with a reduction in NF-κB activity and increased expression of 
inflammatory genes. (84) These changes in bronchial biopsies may reflect the 
changes in NF-κB and HDAC found in lung parenchyma. The main problem 
with using biopsies is that we are not sure how representative they are of what 
is happening in the whole lung. 
 
6. Leptin 
Weight loss is common among patients with COPD and has a significant 
negative impact on mortality in this condition (figure 1.6). (85) The cause of this   33
weight loss is far from completely understood but has been associated with an 
increase in inflammatory cytokines, especially TNF α. (86) Although the 
increased work of breathing could account for some of this loss, the fairly new 
view that COPD is systemic inflammatory disease is also gaining credence.  
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Figure 1.6. BMI and mortality according to stage of COPD using FEV1 
percentage predicted. Taken from (85). 
 
Leptin is an adipocyte-derived hormone coded by the ob gene which plays an 
important role in energy homeostasis by signaling the brain about the amount of 
adipose tissue stored in the body. After interaction with specific receptors 
located in the central nervous system and in peripheral tissues, leptin induces a 
complex response, including control of body weight and energy expenditure. 
Improvements in lipid metabolism and glucose homoeostasis, and increased 
thermogenesis, are considered to be some of the important metabolic effects of 
leptin. Circulating leptin levels alter according to the body mass index (BMI) of a 
patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Serum leptin levels and percentage body fat. (87) 
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Takabatake et al investigated serum leptin levels, along with circulating TNF α 
and its receptor (sTNF-R) in 31 patients with COPD and 15 age-matched 
healthy controls. The body mass index (BMI) and percent body fat (%fat) were 
significantly lower in the COPD patients than in the healthy controls. Serum 
leptin levels were also significantly lower in the COPD patients than in the 
healthy controls. Importantly, circulating leptin levels did correlate well with BMI 
and percentage fat (figure 1.7), but not with TNFα or with sTNF-R levels in the 
COPD patients. This data suggests that circulating leptin is independent of the 
TNFα system and is regulated physiologically even in the presence of cachexia 
in patients with COPD. (87) 
 
A study into the differences in leptin levels between patients with chronic 
bronchitis and emphysema has been performed by Schols et al. (88). They 
studied patients with COPD and characterised their disease according to 
spirometry and features on high-resolution CT (HRCT). They found that as 
expected based on the lower fat mass, that mean detectable plasma leptin was 
significantly lower in the patients with emphysema compared with patients with 
chronic bronchitis.  
 
Postmortem studies of patients who died in the Warsaw Ghetto during World 
War II suggested that death from starvation was associated with pulmonary 
emphysema. (89, 90) To determine whether anorexia nervosa is associated 
with an increased risk of pulmonary emphysema, Coxson and co-workers 
examined BMI, pulmonary function, and CT of the chest in 21 subjects with 
anorexia nervosa and 16 control subjects (91). They found greater CT 
measurements of emphysema in subjects with anorexia, a correlation between 
the BMI and the CT measures of emphysema in all subjects examined, and a 
correlation between diffusing capacity and CT measurements in subjects with 
anorexia. These results demonstrate emphysema-like changes in the lungs of 
chronically malnourished subjects.  
 
7. B-type natriuretic peptide 
The structure of atrial natriuretic peptide (ANP) was identified in 1984, and in 
1988 a compound was isolated from pig brain that caused natriuretic and 
diuretic responses similar to ANP. This was called brain natriuretic peptide 
(BNP) although the main sight of synthesis is the ventricular myocardium. The   36
stimulus for both ANP and BNP is myocardial stretch, rather than transmural 
pressure loads. (92) 
 
BNP is a 32 amino acid peptide hormone, the gene of which lies on 
chromosome 1. In plasma, the intact 108 amino acid prohormone (pro BNP), 
the biologically active BNP, and the remaining part of the prohormone, N-
terminal (NT)-pro BNP can be measured by immunoassay. (93) 
 
Prohormones in normal left ventricular myocytes are not stored in significant 
amounts, so it takes several hours after acute myocardial stretch for the plasma 
natriuretic peptide levels to increase significantly after the onset of acute 
myocardial stretch. 
 
These hormones increase glomerular filtration rate and inhibit sodium 
reabsorption, causing natriuresis and diuresis. These hormones also inhibit 
cardiac sympathetic nervous system activity and the renin-angiotensin-
aldosterone axis. BNP has been shown to predict cardiac disease state, and 
prognosis better than ANP. BNP has been shown to be the best discriminatory 
marker to differentiate cardiac dyspnoea from all other cause of dyspnoea in a 
whole series of trials. (94) There is also a close association between BNP and 
functional New York Heart Association (NYHA) class. (95) BNP is also a 
predictor of all cause mortality in those patients with chronic heart failure.  (96) 
 
With regards to ventricular function in respiratory medicine we are more 
interested in right heart dysfunction, and BNP has been shown to be raised in 
patients with pulmonary hypertension, cor pulmonale and pulmonary embolism. 
(93) BNP has been shown to increase in proportion to the degree of right 
ventricular dysfunction, but to a lesser degree compared to left ventricular 
dysfunction. In right ventricular dysfunction raised concentrations of BNP is a 
predictor for increased risk of death, even in cor pulmonale and primary 
pulmonary hypertension. In pulmonary embolism low BNP levels within 4 hours 
of admission are associated with an uneventful hospital admission, and may be 
useful in identifying patients for treatment in an outpatient setting. (97) 
 
In patients with decompensated heart failure treatment with diuretics and 
vasodilators results in a rapid fall in BNP concentrations. (98)  Whether this is 
true in acute respiratory disease has yet to be studied in a significantly sized   37
study. It has been shown that plasma BNP levels are significantly raised in 
patients with chronic respiratory failure complicated by cor pulmonale. In the 
same study comparisons of patients with lung cancer, and those with chronic 
respiratory failure not complicated by cor pulmonale, were not significantly 
different. Plasma BNP levels showed a weak correlation with systolic 
pulmonary arterial blood pressure, but no link with the degree of hypoxia. (99) 
 
In patient with pulmonary hypertension secondary to COPD, BNP and ANP 
levels correlate with levels of endothelin 1 in the pulmonary vasculature. ANP 
and BNP may modulate the pulmonary vascular tone by interacting with 
endothelin 1 in these patients. (100) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. from leuchte (101) BNP measurements and PAH as predictors of 
mortality.  
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Recombinant human BNP is now available for treatment of decompensated 
heart failure, (102) its benefit over traditional treatments such as dobutamine 
and milrinone has yet to be proven. Another new treatment, ANP/BNP inhibitors 
have also been developed, and subject to phase 2 studies comparing 
traditional treatment with ACE inhibitors (ACEi). The results from this trial were 
disappointing however and did not show an advantage in primary end points 
over ACEi. (92) Angio-oedema was also a worrying common side effect (2.2% 
on BNP inhibitors compared to 0.7% taking enalapril).  
 
A recently published study (101) has studied the possibility of BNP being used 
as a biomarker; BNP levels were measured in 176 consecutive patients with 
various pulmonary diseases (50% COPD, 50% restrictive lung disease). Right 
heart catheterization, lung functional testing, and a 6-min walk test were 
performed. The mean follow-up time was nearly 1 yr. Significant pulmonary 
hypertension (mean pulmonary artery pressure > 35 mm Hg) was diagnosed in 
more than one-fourth of patients and led to decreased exercise tolerance and 
life expectancy. Elevated BNP concentrations identified significant pulmonary 
hypertension with a sensitivity of 0.85 and specificity of 0.88 and predicted 
mortality. Moreover, BNP served as a risk factor of death independent of lung 
functional impairment or hypoxemia in uni- and multivariate analysis. (figure 
1.8) 
 
1.4 Smoking and COPD 
 
Airway Inflammation and smoking cessation in patients with COPD 
Smoking cessation is the only currently available treatment that is effective in 
slowing down the accelerated decline in FEV1 and thus progression of COPD. 
However, the exact role of smoking cessation on airway inflammation in COPD 
is still unknown. A few cross-sectional studies have investigated effects of 
smoking cessation by comparing smokers and ex-smokers with COPD (38), but 
there have been few good longitudinal studies comparing levels of inflammation 
before and after smoking cessation. Airway inflammation in bronchial biopsies 
and sputum does not differ between smokers and ex-smokers, except for some 
cytokines (IL- 8, IL- 6, soluble TNF-receptor (sTNFR) 75 and sTNF-R55). (57) 
Furthermore, Rutgers et al. showed that airway inflammation was more 
extensive in ex-smokers with COPD than in healthy ex-smokers. (103) 
Together, these cross-sectional studies suggest that there is ongoing   39
inflammation in COPD after smoking cessation.  A recent study has compared 
patients with COPD who quit smoking vs. asymptomatic quitters. This study 
showed that in the 12 patients with COPD who successfully ceased smoking, 
airway inflammation persisted in bronchial biopsies, while the number of 
sputum neutrophils, lymphocytes, IL-8 and eosinophilic-cationic-protein levels 
significantly increased at 12 months. In the 16 asymptomatic smokers who 
successfully quit, inflammation significantly reduced (i.e. number of sputum 
macrophages, percentage of eosinophils and IL-8 levels) or did not change. 
(61) 
 
Histone acetylation 
Histones are the core in which chromatin is wound around. In the closed state 
gene induction is prevented, and excludes the binding of the enzyme RNA 
polymerase II (RNAPII) which activates the formation of mRNA.  Gene 
transcription only occurs when the chromatin structure is opened up with 
unwinding of the DNA so that the RNAPII and basal transcription complexes 
can now bind to the naked DNA to initiate transcription. Each histone core has 
a long terminal, which is rich in lysine residues that may be acetylated, thus 
changing the electrical charge of the core histone. This results in acetylation of 
core histones, thereby reducing their charge, which allows the chromatin 
structure to transform from resting closed conformation to an activated open 
form. This allows the binding of TATA box-binding proteins (TBP), TBP-
associated factors and, finally, RNAPII. Removal of the acetyl groups is 
associated with packing of the chromatin and a lack of gene expression or gene 
silencing. (104) 
 
Histone Deacetylases (HDACs) play a critical role in the suppression of gene 
expression by reversing the hyperacetylation of core histones. There are 11 
different HDACs in mammalian cells. There is evidence that these different 
types target different patterns of acetylation and, thereby, target different genes. 
Trichostatin A (TSA) is a nonselective inhibitor of HDACs and in alveolar 
macrophages it leads to the increased expression of inflammatory genes such 
as GM-CSF and IL-8. This suggests that HDACs normally act to suppress the 
expression of inflammatory genes. Atypical nicotinamide adenosine 
dinucleotide-dependent sirtuins are proteins that deacetylate nonhistone 
proteins and are thought to play a role in programmed cell death in 
mononuclear cells.   40
 
In COPD there is a marked reduction in the activity of HDAC2 in the lung 
parenchyma, and this is correlated to disease severity (in those with GOLD 
stage IV there is more than a 95% reduction in the expression of HDAC2) 
Reduced HDAC2 is related to a greater intensity of IL-8, and is also related to 
resistant anti-inflammatory effects of corticosteroids.  (84) 
 
Adenovirus increases the expression of inflammatory genes in epithelial cells 
via the Adenoviral E1A protein which interacts with HAT-containing co-
activators such as CBP. In COPD there is evidence for latent adenoviral 
expression and increased expression of E1A. This may partially explain the 
inflammation in COPD patients. COPD patients are largely unresponsive to 
corticosteroids. This lack of response to corticosteroids may be explained, at
 
least in part, by an inhibitory effect of cigarette smoking
 and oxidative stress on 
HDACs, thus interfering
 with a critical anti-inflammatory action of 
corticosteroids. There is a striking reduction in the activity and
 expression of 
HDACs in peripheral lung of patients with COPD. Even in patients with COPD 
who have stopped smoking, the
 corticosteroid resistance persists and these 
patients
 are known to have continuing oxidative stress. The mechanisms
 
whereby oxidative stress and cigarette smoking lead to selective
 dysfunction of 
HDACs are currently under investigation. (105). There is evidence that the 
administration of low-dose theophylline restores the normal level of HDAC in 
macrophages of patients with COPD, the relevance of this to clinical practice 
has yet to be fully explored, and this is a novel therapeutic target. (106) 
 
 
1.5 Measurements of COPD severity 
 
MRC Dyspnoea score 
Current guidelines define the severity of COPD in terms of FEV1, but the 
correlation between airways obstruction and exercise performance is modest. 
(48) Health status measurements such as that provided by the St George's 
Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Questionnaire 
(CRQ) provide well validated measurements of disability and handicap due to 
COPD, but these are complex to administer and score. A simple and 
standardised method of scoring disability that allowa patients and patient 
populations to be categorised in the manner analogous to the New York Heart   41
Association grading for disability due to heart failure has been devised, the 
Medical Research Council (MRC) dyspnoea scale has been in use for many 
years for grading the effect of breathlessness on daily activities. It is graded as 
such: 
 
Grade 1:  "I only get breathless with strenuous exercise". 
 
Grade 2: "I get short of breath when hurrying on the level or up a slight hill". 
 
Grade 3: "I walk slower than people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace on the 
level" 
 
Grade 4: "I stop for breath after walking 100 yards or after a few minutes on the 
level".  
 
Grade 5: "I am too breathless to leave the house". 
 
It is particularly noteworthy that the FEV1 is a poor indicator, and does not 
relate to disability as measured using the MRC scale. Patients’ performance on 
a shuttle walking test is related to the level of disability, and the mean scores 
clearly deteriorate as disability increased across the MRC groups. (107) 
 
The MRC scale has also been shown in some circumstances to be a better 
predictor of mortality than FEV1 (figure 1.9). (108) It is also used as a variable 
in the BODE index. (109), and has been extensively studied. (110) 
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            MRC Dyspnoea Scale                                  ATS grading based on FEV1 
       
  
Fig 1. 9. Patient survival – MRC vs. FEV1 as a predictor for mortality in patients 
with COPD. (108) 
 
Other measures in COPD 
Celli et al. have studied in detail combinations of measures to come up with 
another scoring system to try and predict life expectancy in patients with COPD. 
They have devised the BODE index, B – Body Mass Index, O – Degree of 
airflow Obstruction, D – MRC Dyspnoea score, and E- Exercise capacity as 
measure by the 6-minute walking test. (1) The BODE index is a multi-
dimensional 10-point scale in which higher scores indicate a higher risk of 
death. Celli et al. validated the index in a cohort of 625 patients, with death from 
any cause and from respiratory causes as the outcome variables. They found 
that patients with higher BODE scores were at higher risk for death; the hazard 
ratio for death from any cause per one-point increase in the BODE score was 
1.34 (95 percent confidence interval, 1.26 to 1.42; P<0.001), and the hazard 
ratio for death from respiratory causes was 1.62 (95 percent confidence 
interval, 1.48 to 1.77; P<0.001). The scoring system is shown below in figure 
1.10 below.  
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Figure 1.10. From Celli, Cote et al. 2004 BODE index (1) 
 
The group concluded that the scoring system was better than FEV1 at 
predicting risk of death. They have shown the results graphically comparing the 
ATS grading system using FEV1 and the BODE index. (figure 1.11)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Comparison of survival curves BODE index vs. American Thoracic 
Classification (1) 
 
1.6 Sputum microbiology   44
 
Induced Sputum – Microbiology and Cell Counts 
The method of inducing sputum in patients with COPD, even during acute 
exacerbations has been found to be safe if conventional methods and safety 
procedures are utilised. (111, 112). Hypertonic saline is a potent 
bronchoconstrictor; this knowledge is invaluable if to be used in patients already 
suffering from an acute exacerbation. Induced sputum also contains a higher 
proportion of viable cells than spontaneous sputum. It has also been shown 
that there are no significant differences between the sputum samples obtained 
at seven minutes, and at 14 minutes of hypertonic saline nebulisation in 
patients with COPD, as opposed to asthma where there are significant 
differences. (113) With regards to measurement of inflammatory markers there 
is no obvious difference between those obtained from spontaneous as opposed 
to induced sputum. 
 
Inducing sputum in high risk patients involves a slightly modified technique to 
reduce the risk of significant bronchoconstriction during the procedure.  
 
Bacteria in sputum 
The bacterial flora in COPD patients in the stable and exacerbation states has 
been extensively studied. The sputum in healthy control subjects is an almost 
sterile environment whilst patients with COPD harbour a variety of pathogenic 
and non-pathogenic organisms.  
 
The three most common bacterial isolates are Haemophilus influenzae, 
Streptococcus pneumoniae, and Moraxella catarrhalis. The role of bacteria in 
causing exacerbations is controversial because the same organisms may be 
isolated in up to 30% of patients when clinically stable. This phenomenon, 
termed ‘‘bacterial colonisation’’, is associated with continued cigarette smoking 
and increasing severity of underlying disease. (114) Much of the evidence that 
bacteria are an important cause of exacerbations is, therefore, extrapolated 
from the benefit seen in trials of antibiotics. The presence of colonisation is not 
benign and may itself modulate exacerbation frequency.  A recent study by 
Sethi has suggested that exacerbations may be the result of acquisition of new 
strains of bacteria. (115) In a study by Patel in patients with stable COPD 50% 
were colonised by a possible pathogen. (116) 
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Induced sputum seems to be the method of choice to acquire samples; 
however, there are no convincing data that it achieves a different result from 
spontaneously produced samples. There are now many studies that show that 
induced and spontaneous sputum provide results that are comparable. (116-
118) A recent study by Marin et al. on 32 patients with COPD showed that 
bacterial isolation using both methods achieves the same result; however, 
induced sputum techniques allow 1/3 of patients unable to expectorate 
spontaneously to produce sputum. (119) Stable COPD patients often have 
lower airway bacterial colonisation which may be an important stimulus to 
airway inflammation and thereby modulate exacerbation frequency. There are 
several arguments regarding the findings of bacteria in the lower airway and 
exacerbations of COPD. The main one centres on the fact that bacteria are 
isolated at the same frequency in stable COPD patients and during an acute 
exacerbation. (120) So is the finding of bacteria in the lower airways an 
epiphenomenon? (121) If bacterial pathogens were playing a role in AECOPD, 
one would expect a neutrophilic inflammatory response in the airways to the 
acute infection. Therefore, one would expect that airway inflammation during 
AECOPD should be related to sputum culture results. 
 
Risk factors for colonisation include the degree of airways obstruction, and 
current smoking. (122) The presence of bacterial colonisation is also related to 
the colour of the expectorated sputum (figure 1.12). In a study of patients with 
COPD presenting to primary care, the presence of green (purulent) sputum was 
94.4% sensitive and 77.0% specific for the yield of a high bacterial load and 
indicated a clear subset of patient episodes identified at presentation that was 
likely to benefit most from antibiotic therapy.  (123) In an editorial review on the 
relationship of bacteria to lung host defences, it was suggested that it should be 
possible to separate the presence of bacteria as commensals in the airway 
from those causing an infection. (124) The latter would be expected to be 
accompanied by activation of secondary host defences, which include 
increased neutrophil recruitment to the airways. This neutrophil influx should be 
associated with a change in secretions from mucoid to purulent (because the 
myeloperoxidase from the neutrophils is green), and the process would reverse 
after antibiotic therapy that reduced or eliminated the bacterial load, thereby 
leading to resolution of the secondary host response. 
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Figure 1.12 The relationship between sputum colour and total neutrophil count 
from patients with an exacerbation of COPD. From (123) 
 
 
 
 
 
 
Serologic evidence of atypical bacterial infection, mostly by Chlamydia 
pneumoniae, is seen in 5 to 10% of exacerbations. (125) However, a recent 
study in AECOPD using Real-time PCR to detect C.pneumoniae or 
Mycoplasma failed to identify either organism in the sputum. (126) Serologic 
evidence of atypical bacterial infection, mostly by Chlamydia pneumoniae, is 
seen in 5 to 10% of exacerbations. (125) However, a recent study in AECOPD 
using Real-time PCR to detect C.pneumoniae or Mycoplasma failed to identify 
either organism in the sputum. (126) 
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Figure 1.13. H.Influenze is associated with high IL-8 levels when a colonizing 
bacteria in COPD. (127) Bacterial colonisation is associated with exacerbation 
frequency and a higher IL-8 concentration. (118) 
 
 
 
Bacterial pathogens are isolated from sputum in about 50% of exacerbations.  
The prevalence of each in the study by Patel was as follows, Haemophilus 
influenzae (53.3%), Streptococcus pneumoniae (33.3%), Haemophilus 
parainfluenzae (20%), Branhamella catarrhalis (20%) and, Pseudomonas 
aeruginosa (20%). The presence of lower airway bacterial colonisation in the 
stable state was found to be related to exacerbation frequency. Patients 
colonised by H influenzae in the stable state reported more symptoms, 
increased sputum purulence at exacerbation, and had higher IL-8 levels than 
those not colonised. (118) (see figure 1.13) They also found that patients 
colonised by H. influenzae in the stable state reported more symptoms and 
increased sputum purulence at exacerbation than those not colonised. 
  
The elevation in inflammatory markers in patient colonised by bacteria was 
confirmed by Sethi et al. who examined sputum from 45 patients with acute 
exacerbations of COPD managed as outpatients. The correlation of 
inflammatory markers to bacterial type is shown in the figure (1.13 above). The 
authors of this study concluded that increased airway inflammation associated 
with isolation of H influenzae and M catarrhalis supports an aetiological role of 
these pathogens in AECOPD. Both these organisms are increased in those 
who continue to smoke. (127) 
 
H influenzae and its products reduce mucociliary clearance, increase mucus 
secretion, and cause bronchial epithelial damage in vitro. The lipo   48
oligosaccharide of H influenzae induces IL-8, IL-6, and TNF-α secretion from 
bronchial epithelial cells in vitro. (128) It is, therefore, likely that a similar 
inflammatory process is being engendered by these mucosal pathogens during 
exacerbations of COPD. 
 
Several bronchoscopic studies of distal airway bacterial flora in AECOPD have 
shown that H influenzae and M catarrhalis are often present in concentrations 
of > 10
3/mL in the distal airways during AECOPD. It may be that the particular 
strain of an organism is different during exacerbation than when isolated as a 
coloniser in the stable condition. This has been shown with Moraxella 
catarrhalis, Streptococcus pneumoniae, and Haemophilus influenzae. (115, 
129) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14. Shows the pathogens recovered in induced sputum during the 
stable state. (39 patients) from (118) 
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* 
The frequency of exacerbations also seems to contribute to the long term 
decline in lung function of patients with moderate to severe COPD. In a study 
by Donaldson et al., 109 patients with moderate to severe COPD were followed 
over 4 years (FEV1 0.7-1.3L). These patients experienced 757 exacerbations. 
Patients with frequent exacerbations had a significantly faster decline in FEV1 
of –40.1 ml/year than infrequent exacerbators in whom FEV1 changed by –32.1 
ml/year. Frequent exacerbators also had a greater decline in FEV1 if allowance 
was made for smoking status. Patients with frequent exacerbations were more 
often admitted to hospital with longer length of stay. Whether these declines in 
FEV1 are clinically important is debatable – but they do represent a 25% 
difference between the 2 groups. (130) (figure 1.15) 
 
 
Figure 1.15. Frequent exacerbators have a greater decline in FEV1 if allowance 
was made for smoking status. * The original legend from the paper is wrong, 
open circles represent the frequent exacerbators and closed circles infrequent 
exacerbators (1) 
 
Haemophilus influenzae colonizes the respiratory tract of patients with COPD, 
often presenting with a pattern in which periods of negative sputum cultures are 
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preceded and followed by isolation of apparently identical strains. To 
investigate whether the strains preceding and following episodes of 
negative cultures were indeed the same, Murphy and colleagues performed 
molecular typing on isolates of H. influenzae collected monthly in a prospective 
study. (131) During a 7-year study involving 104 patients, they detected 122 
episodes of negative cultures lasting 1 month or more, which were preceded 
and followed by isolation of an apparently identical strain of H. influenzae. 
Seventeen such episodes of negative cultures, lasting 6 months or more, were 
studied in detail to test the hypothesis that these periods of negative cultures 
represented continuous colonization by the same strain of H. influenzae. 
Molecular typing by three independent methods established that the strains 
preceding and following the episodes of negative cultures were indeed 
identical. Strain-specific H. influenzae DNA was detected in some of the sputum 
samples that had yielded negative cultures. These results show that some 
patients with COPD are persistently colonized with H. influenzae, and that 
sputum cultures underestimate the frequency of colonization of the respiratory 
tract by H. influenzae. The study also suggests that chronic bacterial 
colonization may significantly contribute to airway inflammation and to the 
course and pathogenesis of COPD. To test the hypothesis that the immune 
response to the homologous (infecting) strain of H. influenzae may have a 
limited ability to kill other (heterologous) H. influenzae strains, and thus it may 
protect against recurrent exacerbations caused by homologous strains, Sethi et 
al. collected sputum and serum samples in 81 patients with COPD monthly and 
during exacerbations. They found that, after exacerbation, an immune response 
to homologous H. influenzae occurs in 61% of cases with newly acquired 
strains as compared with 21% of cases with pre-existing strains. New 
bactericidal antibodies developed after COPD exacerbations were highly strain-
specific, showing bactericidal activity for only 12% of heterologous strains. 
(129) These results suggest that, after an exacerbation of COPD associated 
with H. influenzae strain, serum antibodies to the infecting strain develop in the 
majority of cases with newly acquired but homologous strains, and that the 
immune response to the homologous strain may not protect against infectious 
exacerbations by heterologous strains of H. influenzae. These observations 
further support the role of H. influenzae in a large proportion of COPD 
exacerbations and, by showing the limited immune response to heterologous 
strains of H. influenzae, may explain the mechanism of recurrent exacerbations 
with H. influenzae in COPD. In fact, although patients produce strain-specific   51
antibodies to homologous strains of H. influenzae after exacerbations, the 
immune response leaves the host susceptible to reinfections by other 
heterologous strains of H. influenzae.  
 
Phagocytosis of non typeable Haemophilus influenzae (NTHI) by alveolar 
macrophages of smokers has been accompanied by increased bactericidal 
activity compared with alveolar macrophages of nonsmokers. In a study of the 
effectiveness of alveolar macrophages to clear NTHI they found that alveolar 
macrophages from ex-smokers displayed immunological properties that were 
more like alveolar macrophages of non-smokers. (132) 
 
 
 
Viruses 
Evidence accumulated over the past few years has to point to a clear 
association between viruses and AECOPD. Virus infection, identified by a four-
fold rise in antibody titre or by viral isolation, was found almost 30 years ago by 
Buscho to cause up to a third of exacerbations. (133) Since then, with the 
development of PCR techniques, viral infection has been found in most studies 
to be the cause of an exacerbation in over 50% of patients. Viral infections 
seem to be associated with smoking status, being more common in current 
smokers. (134) Viruses also seem to be responsible for secondary bacterial 
infections by facilitating the attachment of bacteria to the epithelium. (135) The 
most common viruses involved in AECOPD are shown in table 1.3. 
 
Rhinoviruses are one of the main virus species isolated during acute 
exacerbations. Rhinoviruses are an RNA picornavirus and are responsible for 
the common cold. They are spread from person to person by infected 
respiratory secretions. Studies in childhood asthma have shown that viruses, 
especially rhinovirus, can be detected by polymerase chain reaction (PCR) in 
nasopharyngeal samples from a large proportion of these exacerbations. 
However, the role of rhinovirus in COPD exacerbation has been unclear until 
recently. In a study by Seemungal, it was found that rhinovirus was associated 
with 23% of COPD exacerbations; the virus being detected with higher 
frequency in induced sputum from the lower airway, compared to upper airway 
specimens. Rhinoviruses were associated with a greater rise in lower airway IL-
6 levels and total symptom score at COPD exacerbation. (136) Rhinoviruses   52
are also associated with active smoking and the patient’s pack year history. 
(137).  
 
There are a number of ways that rhinovirus infection may be involved in 
exacerbations. Rhinovirus attaches to airway epithelium by ICAM-1 which 
promotes the recruitment of inflammatory cells via NFκB. (138, 139) Rhinovirus 
also interacts with the bacterial flora by increasing the expression on epithelial 
cells of platelet aggregation receptor, this allows for greater adherence by 
Streptococcus pneumoniae at least in in-vivo studies. (table 1.4) 
 
 
 
Viruses  Rhinovirus 
  Coronavirus 
  Influenza A and B 
  Parainfluenza 
  Adenovirus 
  Respiratory Syncitial Virus 
   
Atypical Organisms  Chlamydia Pneumoniae 
  Mycoplasma Pneumonia 
 
Table 1.3. Respiratory viruses and atypical organisms involved in 
exacerbations of COPD 
 
 
Other viruses associated with AECOPD are RSV, influenza A and B, 
parainfluenza, adenovirus, and metapneumovirus. Lower levels of influenza as 
a cause of exacerbations are associated with the increasing uptake of the 
influenza vaccine. (140) 
 
Human metapneumovirus is a paramyxovirus that was discovered in 2001 in 
the Netherlands. Epidemiological (UK English) studies have shown it to be a 
major cause of acute respiratory tract infection in normal infants and children 
worldwide, with a seasonal occurrence and spectrum of clinical illness most 
similar to the closely related respiratory syncytial virus. The greatest prevalence 
of severe disease requiring hospitalization in otherwise healthy children   53
appears to be in those aged between 6 and 12 months, older than the peak age 
of hospitalizations for respiratory syncytial virus. Human metapneumovirus is 
also a significant cause of acute respiratory disease in adults, particularly the 
elderly and those with co morbid conditions such as chronic obstructive 
pulmonary disease, asthma, and cancer. Because there is no rapid diagnostic 
assay, RT-PCR is most widely used.  
 
In a recent study 194 samples from patients with acute exacerbations of COPD 
were analysed using RT-PCR assays for picornaviruses, coronaviruses 229E 
and OC43, influenza A and B viruses, respiratory syncytial virus, parainfluenza 
types 1–3 viruses, and human metapneumovirus and a PCR assay for 
adenoviruses. RT-PCR assays identified an additional 35 respiratory virus-
associated illnesses not identified previously by cell culture or serology (n=46). 
Picornaviruses and coronaviruses were the most common viral infections 
identified only by RT-PCR. Overall, 41.8% of the acute respiratory illnesses 
evaluated were associated with a respiratory virus infection, with 
picornaviruses, coronaviruses and influenza viruses being the most common 
infections recognized. No Human metapneumovirus infections were identified 
by RT-PCR assay. Another study, however, found the presence of 
metapneumovirus in 7% of patients during an acute exacerbation. (59). A 
recent paper also reported detection of hMTP, this virus was only present in 
combination with another rhinovirus. (141) 
 
 
Potential mechanisms of viral infection to cause exacerbations of COPD 
 
Upregulation of ICAM1 
Increase expression of platelet aggregation receptor 
Increase recruitment of inflammatory cells 
Increased oxidant stress 
Increased systemic and airway endothelin-1 
 
 
Table 1.4 Potential mechanisms of viral infection to cause exacerbations of 
COPD 
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1.7 Cell counts 
 
Cell Counts In Induced Sputum. 
Airway inflammation is also thought to play a key role in the pathogenesis of 
COPD. The cellular inflammatory response is characterised by an increase in 
neutrophils, macrophages and CD8 positive T-lymphocytes in small and large 
airways, as well as observed in the lung parenchyma itself. The major type of 
cell in induced sputum is the neutrophil, the quantity of which is associated with 
the severity of the airflow limitation. Sputum represents a non invasive marker 
that is potentially useful for disease monitoring; however there has been 
observed independence in factor analysis between airways inflammation (as 
measured by cell count in induced sputum, and not cytokines) and lung 
function. (28) 
 
Neutrophils and eosinophils predominate in sputum, macrophages and 
lymphocytes predominate in bronchoalveolar lavage, and lymphocytes 
predominate in bronchial biopsies. In cigarette smokers with COPD, the degree 
of neutrophilia relates loosely to the degree of chronic airflow limitation. (69) 
Some patients with chronic bronchitis or COPD have an increase in the 
proportion of eosinophils in sputum, as is characteristically seen in uncontrolled 
asthma and in non-smokers with eosinophilic bronchitis without asthma. (142). 
Eosinophils have also been reported to increase in some exacerbations of 
COPD. (122) The prevalence of sputum eosinophilia in COPD has not been 
examined in a population study. Sputum eosinophilia is important because it 
appears to be associated with clinical improvement. When eosinophils have 
been observed in the sputum of patients with COPD they are also associated 
with eosinophilic cationic protein and eosinophilic peroxidase suggesting that 
the eosinophils have degranulated. This maybe the result of neutrophil elastase 
levels in COPD. Although some exacerbations of COPD are associated with 
sputum eosinophilia, they are associated more usually with neutrophilia. 
 
A recent study published by Papi, who examined the aetiology of 64 patients 
hospitalised with COPD, showed exacerbations with a viral origin, alone or in 
combination with a bacteria exhibit a sputum eosinophilia compared to sputum 
from patients with only bacterial detected. Neutrophil counts were similar in all 
groups. (Figure 1.16) (141) 
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Figure 1.16. A recent study published by Papi observed exacerbations with a 
viral origin, alone or in combination with a bacteria exhibit a sputum eosinophilia 
compared to sputum from patients with only bacterial detected. (141)  
 
Induced sputum in COPD contains mainly neutrophils at a percentage that is 
almost reciprocal to that of macrophages in healthy volunteers. (112) These 
observations are in line with previous findings of high percentages of 
intraluminal neutrophils and confirm previous studies demonstrating an 
increased number of neutrophils in bronchoalveolar lavage fluid. (143) The 
finding that the highest neutrophil percentages are found in patients with the 
worst airflow obstruction is in agreement with the hypothesis that neutrophilic 
inflammation of the small bronchi are an important factor in the pathogenesis of 
airflow limitation in COPD. It has been shown that small bronchi and bronchioli 
are the major site of increased airflow resistance in COPD and that 
inflammatory changes at these sites correlate with airflow limitation. (144) 
Assuming that induced sputum contains material from the lower airways, this 
technique may be a useful tool to study airway inflammation in COPD. 
 
Peripheral blood and sputum lymphocytes  
The functional activities of both CD4+ and CD8+ T-cells are initiated by the 
binding of specific antigen presented in association with the major 
histocompatibility complex (MHC) on the target cell to T-cell antigen receptors.   56
Once activated, T-cells migrate into the peripheral tissue, the lung in this case, 
which is the site of antigen entry and persistence. 
 
In contrast to the numerous studies which show that lymphocytes play an 
important role in the pathogenesis of asthma, few papers have looked into their 
role in COPD. One of the earliest papers published looking into CD4 and CD8 
cell ratios was published by De Jong, he showed that the percentage of CD8+ 
lymphocytes was significantly higher in non-smoking COPD subjects compared 
to non-smoking healthy control subjects. These authors failed to find a 
difference between ex- and current smokers with COPD. (145)  
 
Other groups have found differences between current and ex-smokers with 
COPD. Thus, Lapperre and colleagues studied 114 patients with COPD GOLD 
stage II and III.  They performed bronchoscopies on these patients and 
measured the number of inflammatory cells in bronchial biopsy specimens; they 
found that ex-smokers had higher number of CD4+ lymphocytes and plasma 
cells than current smokers. They also found that those who stopped smoking 
more than 3.5 years ago also had lower numbers of CD8+ lymphocytes. Their 
observations led them to comment that T-lymphocyte numbers respond to 
current smoking status. (146) These patients had mild disease, were steroid 
naïve and were not exacerbating at the time of the study.  
 
The number of CD4+ T-cells in the lungs of smokers increases significantly 
after 30 yrs of smoking as do the CD8+ T-cells, suggesting that the CD4+ T-cell 
might be playing a role in the inflammatory process. (147) CD4+ T-cell help is 
required for the priming of CD8+ cytotoxic T-cell responses, for maintaining 
their memory and for ensuring CD8+ T cell survival, (148) suggesting that even 
low numbers of CD4+ T-cells could be essential for the development of the 
CD8+ T-cell inflammatory infiltrate found in smokers. 
 
To look at the effect of cigarette smoking on T-cell subsets Tollerud et al 
recruited 282 healthy subjects and performed FACS analysis on their peripheral 
blood. They found that cigarette smoking was associated with a selective 
increase in CD4+ cells compared to non-smokers. These findings were 
reproduced in other study by Bijl and colleagues. (149, 150)  
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In another study samples from lung were obtained at surgery from 15 patients 
who smoked and 6 who had never smoked (147). Neutrophils were found to be 
were the predominant cell in the lung parenchyma of non smokers and smokers 
without emphysema. In smokers with emphysema, the CD3+ and CD8+ were 
the predominant cells (p<0.05) in the alveolar wall. It was concluded that the 
pathogenesis of emphysema might be mediated by T-lymphocytes, mainly 
CD8+ T-cells.  
 
In some ways these studies are contradictory, or the profile of T cell subtypes in 
the blood and lungs are different. 
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CHAPTER 2: METHODS 
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Chapter 2: Methods 1 
 
 
2.1 The pilot project 
This project evolved from a pilot study located at Poole Hospital NHS Trust, 
Dorset, UK (note this thesis is for an international audience). As part of a 
systems review for the inception of a COPD at home project (where patients 
are discharged earlier than would be expected with supportive care at home 
from an experienced nursing team), it was decided to perform full spirometry on 
all patients during their exacerbation to try and determine which patients were 
recovering sufficiently well to enable a safe discharge. This pilot study was 
performed in 2002 and published as an abstract at the ERS conference in 
Stockholm. (2) 
 
A total of 40 patients were followed through their exacerbation. I performed the 
following daily measurements of lung function: FEV1, FVC, and PEFR. The 
results from this study revealed that ex-smokers recovered from their 
exacerbation much more quickly than current smokers in the first few days of 
treatment.  
 
From this pilot we formulated a study hypothesis. 
 
 
2.2 The Hypothesis 
 
In a group of patients with COPD, requiring hospital admission for the treatment 
of an exacerbation I hypothesise that……. 
 
1.   patients with COPD who are ex-smokers (for more than 1 year) recover 
more rapidly from exacerbations than current smokers (as shown by lung 
function tests), due to either a different response to conventional treatment (as 
smokers are known to be partially resistant to steroid treatment) or a different 
disease mechanism;   60
 
2.   this could be due to a difference in the bacterial flora and/or viral 
infection at the time of exacerbation;  
 
3.   it is possible to identify biomarkers that are differentially expressed in 
current and ex-smokers. 
 
 
2.3 The aims of the study 
Based on the hypotheses the aims of my study were to: 
 
1.  follow ex- and current smokers through their acute exacerbation, 
and research differences between the 2 groups that could account 
for the differences observed in the pilot study; 
 
 
2.  see if the findings of the pilot study can be repeated; 
 
 
3.  identify other measures of lung function that may be useful in 
measuring response to treatment during acute exacerbations; 
 
 
4.  identify potential markers that may be of value in monitoring 
response to treatment; 
 
 
2.4 Ethics, and research and development 
Ethics approval was obtained from the Southampton and South West 
Hampshire Research Ethics Committee on 6th July 2006 (ref: 05/Q1702/68). 
The project was accepted on the 4
th July 2006 by the hospital research and 
development committee (ref: RHM MED0636).  
 
2.5 Power calculation 
My pilot study allowed me to undertake power calculation to determine the 
numbers necessary to recruit to find a statistical difference between the 2 
groups at the 5% level.   61
 
The primary outcome for the pilot study was average percentage change in 
FEV1 from baseline averaged over the first week. Using the average 
percentage changes from 20 subjects collected in Poole in 2002, I determined 
the mean (SD) % changes in FEV1 of 8.55(12.70) in ex smokers and 2.17(5.85) 
in current smokers. Based on the pooled standard deviation of 9.9, 28 subjects 
per group should be sufficient to give 80% power in the two sample t−test 
performed at the 5% level, if the mean difference is 6%. This calculation is 
backed up by a previous study by Calverley et al. (151) 
 
2.6 The Study Population 
The population studied were those subject to severe exacerbations of COPD 
admitted to Southampton General Hospital. The project had not been designed 
to look at the whole population of COPD patients because many with mild to 
moderate disease will not experience an exacerbation severe enough to 
warrant admission to hospital. The population represents the more severe end 
of the disease spectrum and it is these patients that are most at risk from 
exacerbations in terms of morbidity and mortality. The patients with severe 
disease also have the most impact on secondary health care in terms of bed 
days and overall expenditure.  
   
Smoking and treatment history were taken and blood cotinine values obtained 
to confirm smoking status. Patients were recruited from either the Respiratory 
Centre of the Southampton General Hospital (which assesses patients suffering 
acute exacerbations in a day hospital setting) or the Acute Medical Unit where 
patients are hospitalised from the Accident & Emergencies Department. 
 
2.7 Exclusion Criteria 
To achieve robust data it was necessary to have strict inclusion and exclusion 
criteria. Patients with a history of asthma, bronchiectasis, carcinoma of
 the 
bronchus, or other significant respiratory disease were excluded from the study. 
A comprehensive history, chest x-ray and reversibility studies were performed 
and used to exclude those patients with other lung pathology. 
   
Other patients excluded were those unable to perform spirometry, those with 
severe type 2 respiratory failure requiring non-invasive ventilation, and patients 
with consolidation on plain chest x-ray.    62
Patients with other causes of dyspnoea such as cardiac disease were excluded 
following a comprehensive history, examination, ECG, measurement of BNP 
levels and chest x-ray. The BNP level and ECG were used as an initial screen 
for congestive cardiac failure, if BNP levels reach those expected to be seen in 
left ventricular dysfunction, then echocardiography was performed to 
confirm/refute cardiac failure. 
 
2.8 Acute Exacerbations – the definition 
For this project we used the definition of an acute exacerbation of COPD from 
the East London group.  
 
The following symptom pattern had to be experienced
 for at least two 
consecutive days for the diagnosis to be made:
 any two of three major 
symptoms (increase in dyspnoea, sputum
 purulence, and increased sputum 
volume) or at least one major
 symptom together with at least one of the 
following minor symptoms - a
 cold (increase in nasal discharge or congestion), 
wheeze, sore
 throat, cough, or fever. These criteria have become standard for 
defining acute exacerbations in the research. (38)  
 
With our own definition: 
 
`An acute exacerbation of COPD is a sustained worsening of the patient's 
condition which could be attributable to their COPD, from the stable state 
and beyond normal day-to-day variations, that is acute in onset and 
necessitates a change in regular medication in a patient with underlying 
COPD. It often presents with the combination of increasing dyspnoea, and 
an alteration in sputum production.` 
 
 
Questionnaires 
The MRC dyspnoea score and St George`s Respiratory Questionnaire (SGRQ) 
were recorded at the time of admission. Both these scores have been validated 
and used extensively in studies.  
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2.9 Spirometry 
 
Equipment  
 
1. Micromedical Spirometer: MicroLoop Cat. No. ML3535  
2. Disposable mouth pieces Micromedical Ltd 66.5mm X 27.8mm X 30mm 
3. Spida 5 Software Cat. No. SD5000 
All from Micromedical Ltd, Rochester, Kent 
 
Methods 
Spirometry was performed daily during the admission using the micromedical 
spirometer ML3535 (Micromedical Ltd, Rochester, Kent). This spirometer has 
been validated in previous studies and meets the American Thoracic Society 
(ATS) criteria for performance. (152) 
 
The following measurements were performed daily at 10am after their morning 
nebuliser (if prescribed): FEV1, FVC, FEV6, IC and PEF. The best of 3 attempts 
was used as standard. The results were recorded in the patients file, and 
uploaded for analysis using the Spida 5 software (Micromedical Ltd, Rochester, 
Kent). The Spida 5 software is an electronic database that allowed us to store 
and analyse the pulmonary function tests from the ML3535 handheld 
spirometer. Some of the patients admitted to hospital with their COPD were 
discharged early (within 7 days) using the COPD early discharge scheme 
implemented in the hospital. In such cases, spirometry was recorded in the 
community by myself or one of the community outreach nurses from the 
Respiratory Centre using the same spirometer. 
 
To standardise the spirometric measurements body weight, height and ethnic 
origin was also recorded. Percentage predicted for each variable was 
formulated using the spida 5 software and recorded.  
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To obtain the measurements necessary subjects were asked to perform the 
following manoeuvres. 
 
1.  Insert mouthpiece and perform tight lip seal. Nose clip was then placed 
to prevent air leakage. 
2.  The patient was then instructed to perform tidal breathing for 3 tidal 
breaths. 
3.  At the end of the last tidal breath the patient was instructed to perform a 
full inspiratory manoeuvre followed by a maximum expiratory 
manoeuvre. 
 
 
This is shown graphically below  
 
 
 
 
 
 
 
 
# 
 
 
 
 
 
Fig. 2.1   Flow volume loop from subject – from Spida 5 software package. 
 
 
 
2.10 ECG 
 
A baseline 12 lead ECG was performed on admission day 1 and recorded in 
the patient’s notes. 
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2.11 Blood Tests 
Venesections were performed on day 1 of the admission and at the 3 monthly 
follow up visit. 
 
 
Equipment  
Vacutainer Systems safety-Lok
TM  Blood Collection Set REF 367282 Becton 
Dickinson and the following vacutainers were used: 3ml EDTA tube (for BNP, 
Full Blood Count), 8ml LH tube (for flow cytometry) 4.5ml Sodium Citrate Tube 
(for clotting, fibrinogen, and to process plasma, 10ml (Z) CAT Tube (to process 
serum). 
 
Methods 
Some of the blood collected was sent to the laboratories of Southampton 
Hospital and analysed for full blood count, CRP, indirect fibrinogen and urea 
and electrolytes. An EDTA sample was also processed and stored at -28° C in 
the biochemistry lab and analysed for BNP. A lithium heparin sample was 
obtained and Cotinine levels were measured in the biochemistry lab. Serum 
and Plasma was processed according to the following method and stored at -
80° C for later analysis. 
 
Plasma 
1) Blood was collected into one 10ml vacutainer for serum (Z) and two 4.5ml 
vacutainers for plasma  (sodium  citrate).    Once collected  the samples in the 
citrate vacutainers were inverted gently 8 times each, but the Z vacutainer was 
allowed  to  rest  undisturbed  at  room  temperature  for  30  minutes  without 
agitation until fully clotted.   
2)  The  citrate  vacutainers  were  then  centrifuged  immediately  at  3,000  rpm 
(1,750g) for 10 minutes at 20
oC. The plasma was collected without disturbing 
the  red  pellet  and  pooled  into  a  15ml  tube,  and  then  aliquoted  into  screw-
capped 2ml tubes. 3 x 500µl samples were stored and frozen immediately at -
80
oC.   
3) The z serum tubes were processed and centrifuged in the same way once 
the 30 minutes had passed and the blood had fully clotted. 
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2.12 Arterial blood gas 
 
Equipment: heparinised syringe for arterial blood puncture and an Arterial 
Blood Gas Machine. 
 
Methods 
Arterial blood collected in a heparinised syringe using the radial artery puncture 
method. The samples were analysed immediately and results obtained for pH, 
PaO2 , PaCO2 , bicarbonate, and base excess. 
 
2.13 Sputum Induction 
Sputum induction was performed on day 1 and, whenever possible, 3 months 
after AECOPD. 
 
Equipment: Nebuliser machine – standard ward based, elephant hosing, face 
mask – standard, salbutamol 5mg, 5 mls 0.9% Normal saline, petri dish, Peak 
flow metre and pulse oximeter. 
 
Methods 
Sputum was induced at the patients’ bedside because of the severity of their 
illness. This patient population is especially susceptible to the 
bronchoconstriction that can be induced by nebulisation with hypertonic saline. 
An alternative but validated method was used for this population. (111, 113, 
117) Due to the fragility of this patient group, prior to sputum induction, all 
patients were pre medicated with 5mg of salbutamol. 
 
Nebulisation with 0.9% saline was commenced using a procedure modified 
from that of Pin et al but using a conventional ward based nebuliser. After 3 
minutes of nebulisation measurement of
 oxygen saturation and spirometric 
tests were performed and nebulisation
 continued if the FEV1 had not fallen by 
more than 20%. Patients were instructed to blow their noses
 and rinse their   67
mouths out with water before expectorating sputum.
 Sputum samples were 
collected throughout the procedure and then placed in a Petri dish. 
 
This method has been shown to be a perfectly safe for sputum collection in 
patients with acute COPD. (111) 
 
2.14 Sputum Processing 
Equipment:  Forceps, falcon tubes, bench rocker, 70µm filter, pipettes various 
eppendorf tubes with screw caps, cytospin, slides, cover slips, 
haemocytometer, trypan Blue, 0.63M dithioerythritol (DTE) in HEPES buffered 
saline (48mg DTE in 50ml HBS) (Sigma, Poole, UK), HEPES buffered saline 
(50mM HEPES pH 7.4, 140mM NaCl) (Sigma), and Protease inhibitor cocktail 
(Sigma cat no:  P8340) (sigma) 
 
Methods 
Sputum processing was performed within 2 hours of induction. A sample of sputum 
was sent to microbiology for cultures using standard guidelines. (153) The 
maximum time allowed from production of sputum to plating for culture was 2 
hours. 
 
The remaining sputum was placed in a Petri dish and forceps were used to select 
the mucoid portions and transfer these into another Petri dish. The samples were 
then mixed thoroughly using forceps and divided into two.  Sample A was 
solubilised with 4X sputum weight of DTE while sample B was solubilised with 4X 
sputum weight of PBS. A protease inhibitor cocktail was then added to the samples 
in the ratio of 22.5µg per g of sputum. After mixing for 30 minutes on a bench 
rocker and filtering both samples through a 70 µm filter the samples are then 
centrifuged at 1,500 rpm (400g) for 10 minutes to form cell pellets. The supernatant 
was carefully removed and put into labelled 1.5ml eppendorf tubes, these were 
then stored for future analysis at –80°C. 
 
The cell pellet from the DTE treated sample was resuspended in 1 ml PBS. A total 
cell count is obtained by mixing10 µl of cell suspension and mixing with 90 µl of 
trypan blue in an eppendorf.  Total cell count and viability per ml was then 
calculated. The HBS was then diluted to obtain approximately 1 x 106 cells / ml. 
Cytospins are assembled and 70 µl of diluted cell suspension is added to slides.   68
This was then spun at 450 rpm (for Shandon Cytospin 2 or as appropriate for 
cytospin model) for 6 minutes. One slide was stained with Diff-Quick or May 
Grunwald Giemsa and air dried. One slide was frozen at -80° C. 
 
 
 
 
 
 
 
 
 
CHAPTER 3: METHODS – PART 2 
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Chapter 3 – Methods 2 
 
 
3.1 RNA extraction from sputum 
 
 
Step A 
 
 
Equipment: Microprep kit (Absolutely RNA® Microprep Kit Catalog number 
400805 Stratagene, La Jolla, USA) this contains: Lysis Buffer, β-Mercaptoethanol, 
(β-ME) (14.2 M), RNase-free DNase I (lyophilized), DNase Reconstitution Buffer, 
DNase Digestion Buffer , High-Salt Wash Buffer (1.67×), Low-Salt Wash Buffer 
(5×), Elution buffer (10 mM Tris-HCl, pH 7.5), RNA-Binding Spin Cups and 2-ml 
receptacle tubes, 1.5-ml collection tubes  
 
 
Method 
 
The RNA from the sputum was extracted according to the following method 
from cells obtained during the sputum processing at a concentration of 
1x10
6cells/ml, and also from 200 µl of the DTE prepared supernatant. There 
were 3 conditions used under which the RNA was extracted. Cells, supernatant, 
and then cell and supernatant. 
 
To minimise cross infection an independent RNA area was used.  
Gloves were sterilized and the pipette disinfected prior to the procedure. The 
gloves and bench were sprayed with RNA’se away spray and filtered tips were 
used at all times.  
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In an eppendorff (1.5ml) 400 µl of lysis buffer from the kit was mixed with 2.8 µl 
of β-Mercapthoethanol to formulate the lysis mix. Two 1.5 ml eppendorfs were 
used and 1ml of cells (1x10
6cells) was centrifuged in the micro-centrifuge for 3 
minutes at 3000 rpm.  The supernatant was then discarded. For one of the 2 
tubes the pellet was resuspended with the 200µl of sputum supernatant and 
with 200 µl of PBS for the other tube. In each tube 200 µl of the Lysis mix was 
added, mixed and then vortexed for 5 seconds. The 2 tubes are then stored at -
80° C. 
 
The RNA was then extracted using a column based method as per the kit 
instructions. In summary an equal volume (usually 100 µl) of 70% ethanol is 
added to the cell lysate and mixed thoroughly by vortexing for 5 seconds. This 
mixture was then transferred to the RNA-Binding Spin Cup that has been 
seated within a 2-ml collection tube. This was then placed in the 
microcentrifuge for 30–60 seconds at maximum speed. The spin cup was 
removed and the filtrate discarded. 500 µl of High-Salt Wash Buffer was added 
to the spin cup and placed in a microcentrifuge at maximum speed for 30–60 
seconds. The filtrate was then discarded. The spin cup was replaced in the 
collection tube. 600 µl of Low-Salt Wash Buffer was then added. The sample 
was then placed in a microcentrifuge at maximum speed for 30–60 seconds. 
We then remove and retain the spin cup, discard the filtrate, and replace the 
spin cup in the collection tube. 300 µl of Low-Salt Wash Buffer was added. The 
sample was placed in a microcentrifuge at maximum speed for 2 minutes to dry 
the fiber matrix. 30 µl of Elution Buffer was then added directly onto the fiber 
matrix inside the spin cup and incubated at room temperature for 2 minutes. 
The sample was then placed in a microcentrifuge for 1 minute. This elution step 
was repeated to increase the yield of total RNA. The RNA was then stored at–
80° C for long-term storage. 
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3.2 Viral PCR 
 
Step B 
Equipment 
 
Primers meta-pneumovirus, adenovirus B & C, influenza virus AH1-AH3-B, 
parainfluenza virus 1-2-3, respiratory syncytial virus A & B, and rhinovirus (all 
sub-types) Were all from PrimerDesign Ltd (Southampton, UK). Buffer 
components were also from PrimerDesign Ltd), while iQ5 Real-Time PCR 
Detection System was from Bio-Rad Laboratories) (Hemel Hempstead, UK). 
Absolutely RNA
® Microprep Kit (Stratagene, Amsterdam Zuidoost, The 
Netherlands)  
 
Mehods 
RNA was extracted from 10
6 sputum cells and/or 200 µl of sputum supernatant 
using the Absolutely RNA
® Microprep Kit (Stratagene, Amsterdam Zuidoost, 
The Netherlands) in RNase-free conditions and directly followed by a liquid-
phase DNase treatment (Ambion/Applied Biosystems, Warrington, UK). 
Reverse transcription reactions, and polymerase chain reactions, were carried 
out using virus-specific primers (PrimerDesign Ltd). For each sample, 5 µl of 
cDNA in 20 µl volume was used for independent TaqMan
® based quantitative 
PCR. In each case, the reaction was optimized with respect to enzymes, buffer 
components (PrimerDesign Ltd), and cycling parameters in iQ5 Real-Time PCR 
Detection System (Bio-Rad Laboratories). For all PCR amplifications positive 
and negative controls were included. 
     
Sputum factors inhibits PCR Virus DNA detection 
All samples were tested by PCR using primers/probes detailed above. After the 
initial run, no signals were positively detectable. We then tested the detection 
kits by performing spiking experiments with short DNA sequences coding for a 
part of the virus genome.  We introduced a sample with 12500 or 800 copies of   72
the RHV positive control DNA sequence. After comparison with the PCR signal 
obtained with non RNA samples, we observed the presence of intrinsic factors, 
which strongly inhibited the PCR reaction in spiked sputum samples (figure 
3.1). We observed this inhibition for all viruses in both the cellular and fluid 
conditions (data not shown). 
 
This inhibitory effect was reduced by diluting the post reverse transcriptase 
reaction product (cDNA) samples. Spiking experiments were then carried out 
on serial dilutions of both, cellular and fluid samples. Dilution was found to 
increase the recovery of the signal with a maximal recovering after 64-fold 
dilution of the samples for the RHV detection. At this point the recovery is near 
to 100% to compare with no RNA spiked positive controls. The recovery rate 
was dependent on the virus, and was also shown to be sample dependant.  
 
We formulated a hypothesis that if the dilution of the sample increased the 
recovery rate of detection of virus DNA sequence by PCR, then this process 
also dilutes the cDNA. To prove this we perfomed two different spiking 
experiments run in parallel. Initially we diluted the sample and then spiked all 
conditions with a known amount of virus DNA sequence; this was compared 
then to spiking the samples and then diluting it to compare the recovery rate of 
detection with the right shift of the signal due to dilution. It was discovered that 
for some types of virus the dilution factor necessary to obtain a maximal 
recovery rate induced a right shift of the PCR signal below the primers/probe 
PCR sensitivity kits.  
 
The demarcation point between the signal recovery and its disappearance had 
to be determined for all virus detection kits. An example of this is shown in 
figure 3.3, which shows the effect of dilution on 2 samples for RHV and FluAH3. 
For these two samples, a dilution factor of 8 has been applied which allowed us 
to detect true positive PCR signals. 
 
An experimental strategy was devised to analyse all samples at the same time. 
We initiated the work by evaluating the sensitivity of all the virus detection kits. 
For this we performed a standard PCR curve for every kit using different 
dilutions of the virus positive sequences. Figure 3.1 shows PCR results 
obtained using serial dilution, from 12500 to 24 copies, of the RSVA positive 
cDNA sequences.). We then performed PCR on all undiluted samples, every   73
sample contained a cDNA equivalent of 10,000 sputum cells or 2 µl of sputum 
fluid. Figure 3.3 shows the PCR curves obtained for Rhinovirus and Flu AH3. In 
all the samples and with each detection kit most of results were negative, 
partially due to the presence of inhibitatory factors.  
 
To analyse the effect of inhibition we calculated for each virus detection kit the 
minimal quantity of virus that could be detected in the samples. To determine 
the "threshold" of detection, according to the standard curve, three different 
quantities of control virus sequences were arbitrary chosen and used to spike 6 
samples chosen at random. 
 
This experimental strategy was then applied for every virus kit, Table 3.1 shows 
the threshold values for each virus detection kit. 
 
RNA was extracted from 30 fluid- and 28 cellular-fraction. The results of which 
are shown in the main paper. 
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Control+ (12500 copies)
Dilution ￿spike constant (on observe l’effet d’inhibition)
Spike ￿ dilution (on observe l’éloignement du signal)
Proof of inhibition – Spiking experiment 
But loose of the signal
B
Dilution better recovery of the signal
C
D - E
A: Sample without RNA + 12500 copies of the positive sequence
B: Sample without RNA + 800 copies
C: Sample with RNA + 12500 copies
D: Sample with RNA + 800 copies
E: Sample without RNA + 0 copies
128x
64x
32x
16x
8x
4x
2x, (-)
(+)
128x
64x
32x
16x
8x
4x
2x
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(-)
A 
32x
16x
8x
16x
32x
(+)
(-)
 
 
Figure 3.1. Experiments to show proof of inhibition.  Detection kits were tested 
by performing spiking experiments with short DNA sequences coding for a part 
of the virus genome. Dilution can lead to better recovery of the PCR signal in 
both the cellular and supernatant fractions. If the samples are diluted too much 
then the signal can be lost 
 
 
 
 
 
 
 
 
 
Dilution leads to better recovery of the signal 
But you can lose the signal 
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Figure 3.2: Intrinsic sputum inhibition factor effects on PCR reaction (example 
shown is for experiments using the rhinovirus detection kit).  
Left panel: a series of dilutions of a single RNA sputum sample was spiked with 
12,500 copies of a rhinovirus specific DNA sequence. PCR curves analyses 
showed that the inhibition effect is reduced with sample dilution. (+): positive 
control: PCR carried out on 12,500 copies of the synthetic DNA control 
sequence in water; (-): PCR carried out on water. 
Right panel: Effect of dilution on real (non-spiked) samples. Rhinovirus PCR 
was carried out on 2 different samples (S1, S2) undiluted and diluted 8 times. 
The analysis of PCR results showed no (or very weak) signals on undiluted 
samples, but after dilution (and reduction of inhibition factors) the PCR results 
became positive. 
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Figure 3.3: The effect of dilution on 2 samples for RHV and FluAH3. For these 
two samples, a dilution factor of 8 has been applied which allows detection of 
true positive PCR signals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compromise, examples with unspiked samples
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FluAH3
No Dilution 8x Dilution
Compromise, examples with unspiked samples
RHV
FluAH3
No Dilution 8x Dilution
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Table 3.1: The PCR threshold was optimised for each individual virus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Treshold  PCR-Ct value
(number of copies)
Adenovirus B 100
Adenovirus C 12
Influenza AH1 12
Influenza AH3 100
Influenza B 50
Metapneumovirus 50
Para-influenza virus 1 12
Para-influenza virus 2 12
Para-influenza virus 3 12
Respiratory syncitial virus A 50
Respiratory syncitial virus B 400
Rhinovirus (all subtypes) 800
Table 1. List of viruses and PCR-treshold of detection
  Threshold 
List of virus and the PCR threshold of detection 
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3.3 Flow Cytometry 
Flow cytometry using the Four-colour FACS Calibur Cell Sorter was used to 
detect the types of cells present in the sputum whether the cells were activated 
or not. 
 
Equipment cluster 
 
Four-colour FACS Calibur Cell Sorter (BD biosciences) 
 
Antibodies used (Table 3.2): 
 
Surface marker  Antibody  Isotype control  Fluorochrome labelled 
CD66b  moIgM 
Fluorescein isothiocyanate–
conjugated (FITC) 
CD11b  ratIgG2b 
Peridinin chlorophyll protein 
(PerCP)-cyanin (Cy)5.5 
Granulocytes activation 
markers 
CD62L  moIgG1  Allophycocyanin (APC) 
CD3  moIgG1  APC  T-cells phenotyping 
markers  CD4  moIgG1  PerCP-Cy5.5 
CD25  moIgG1  R-Phycoerythrin (PE) 
CD69  moIgG1  FITC 
T-cells activation 
markers 
HLA-DR  moIgG2a  PerCP 
 
All antibodies purchased through BD biosciences Oxford UK. 
 
Methods 
Freshly processed sputum cells were suspended in 1 ml of ice-cold Phosphate 
Buffered Saline (PBS) with Ca2+ and Mg2+ (Sigma). Cells were then washed 
with flow cytometry staining buffer (FBS) (PBS, 2% heat-inactivated foetal calf 
serum, 0.09% sodium azide) and incubated for 15 min on ice with 2 mg per 
millilitres of polyclonal human Immunoglobulin (Ig)G (Sigma) to block any non 
specific binding of antibodies  to  Fcγ  receptors.  For  blood  analysis,  100µl of 
whole blood was diluted twice with FBS. For both samples, specific staining 
was then performed with specific fluorochrome-coupled antibodies (anti-CD62L, 
-CD11b, -CD66b for granulocytes and anti-CD3, -CD4, -CD25, -CD69, -HLA-
DR for T-cells and incubated for 45 min on ice. Unbound antibody was removed   79
by washing once with FBS. For whole blood samples, a haemolysis step was 
performed to eliminate red blood cells with a lysis buffer (BD biosciences) for 6 
minutes on ice and then washed with FBS. Cells were analysed on four-colour 
FACS Calibur using Cell Quest software (both from BD Biosciences) 
 
FACS gating strategy for analyses of granulocytes surface marker 
expression in blood and sputum samples.  
 
For both the granulocyte and lymphocyte population only samples with >50 
cells was used for anaylsis. 
 
Initially, cell debris which bind antibodies non-specifically, are excluded by their 
low size and granularity. In respect to their short life, in sputum samples, dying 
granulocytes  are  gated  out  by  virtue  of  their  staining  with  the  DNA-binding 
agent,  propidium  iodide.  The  living  granulocyte  population  is  then  gated 
positively  in  the  forward  and  side-scatter  plot  (high  size  and  granularity). 
Remaining contaminant monocyte/macrophage cells are excluded using their 
autofluorescent property and by staining with CD66b which is not expressed by 
these cells. Different granulocytes activation markers were tested. 
 
FACS gating strategy for analyses of T-cells surface marker expression in 
blood and sputum samples.  
 
As  for  granulocytes,  cell  debris  were  excluded  by  their  very  low  size  and 
granularity and lymphocytes cell T cells are gated positively in the forward and 
side-scatter plot (low size and granularity). CD3+ cells are positively selected 
by  staining  with  anti-CD3  antibody.  From  CD3+  cells,  CD4+  T-cells  are 
detected by using anti-CD4 antibody, CD8 cells were assumed as CD3+ CD4- 
cells. Activation markers expression were analysed on the CD3+ population, 
low size and low granularity.  
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3.4 Luminex – Multiple cytokine analysis 
The Luminex system allows for the analysis of multiple cytokines within a very 
short period of time using antibody binding within a flow cytometry gating 
method. It has excellent reproducibility and correlates well with single ELISA 
methods for cytokine detection. (154) 
 
Equipment 
Luminex assay (Bio-Rad, Hemel Hempstead, UK), recombinant cytokines IL-2, 
IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, TNFα, IFNγ (R & D systems, 
Abingdon, UK), capture and detection antibodies for TNFα (R&D) IL-2, IL-4, IL-
13 capture antibody; IL-5, IL-10, IL-12p70, IL-13 detection antibody (Endogen, 
UK), IFN-γ, IL-6, IL-8, IL-10, IL-12p70 capture antibody; IFN-γ, IL-4, IL-6, IL-8, 
IL-12p70 detection antibody. (GlaxoSmithKline, Stevenage, UK), 96-well filter 
plate (Millipore, Watford, UK), Antibody-conjugated xMAP Carboxylated 
Microspheres (Applied Cytometry Systems, Sheffield, UK), 50 µl of streptavidin-
PE (1 µg/ml in assay buffer - BD Biosciences), STarStation 2.0software 
(Applied Cytometry Systems). 
 
Methods 
Luminex assay (Bio-Rad) was used to determine the concentrations of multiple 
cytokines  (IL-2,  IL-4, IL-5,  IL-6,  IL-8,  IL-10,  IL-12p70,  IL-13,  TNFα,  IFNγ)  in 
patient serum samples diluted 1:5 according to the manufacturer’s instructions.  
Recombinant  cytokines  for  standard  curve  generation  were  purchased  from 
R&D  systems (Abingdon,  UK).   Capture and detection antibodies were from 
R&D (TNFα), Pharmingen, UK (IL-2, IL-4, IL-13 capture antibody; IL-5, IL-10, 
IL-12p70, IL-13 detection antibody), Endogen, UK (IFN-γ, IL-6, IL-8, IL-10, IL-
12p70 capture antibody; IFN-γ, IL-4, IL-6, IL-8, IL-12p70 detection antibody), 
and GlaxoSmithKline (IL-5 capture antibody). HEPES buffered saline (50mM 
HEPES pH 7.4, 140mM NaCl) (Sigma) 
 
50  µl  of  standards  or  diluted  samples  were  placed  on  a  96-well  filter  plate 
(Millipore,  Watford,  UK)  pre-wet  with  50  µl  of  assay  buffer  (PBS,  1%  BSA,   81
0.025%  Triton-X100).  50µl  of  appropriate  antibody-conjugated  xMAP 
Carboxylated Microspheres (Applied Cytometry Systems) were added to each 
well  (1x10
5  microspheres/ml  for  each  conjugated  microsphere  set)  and  the 
plate covered and incubated at 4ºC overnight.  After two  washes with wash 
buffer  (PBS,  0.05%  Tween-20),  50  µl  of  a  cocktail  of  appropriate  detection 
antibodies (500 ng/ml for each antibody) was added to each well and incubated 
on a shaker at 700 rpm for 1 h at room temperature.  After two further washes, 
50  µl  of  streptavidin-PE  (1  µg/ml  in  assay  buffer  -  BD  Biosciences)  and 
incubated on a shaker for 30 min at room temperature at 700 rpm.  The plate 
was  then  washed  twice and  120 µl  of sheath fluid  was added to each well 
before reading on a Luminex xMAP100 machine (Bio-Rad).   
 
Results  were  analysed  using  STarStation  2.0software  (Applied  Cytometry 
Systems). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   82
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4: RESULTS 
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Results 
I screened a total of 138 patients presenting with an acute exacerbation of 
COPD to the acute medical unit. From these patients I recruited to the study 31 
current smokers and 27 ex-smokers. Exceeding the number required from the 
power calculation by 2. Details why certain patients were excluded are shown 
below in figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 : Study design 
 
 
The ex-smokers and current smokers were matched for age, sex, FEV1, 
exacerbation rate, and use of inhaled treatment. The only statistically significant 
difference between the 2 groups was in the total number of pack years. Not   84
surprisingly the current smokers had smoked more cigarettes than the ex 
smokers. (p<0.05) (table 4.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Demographics. 
#=
 Median,  *= Mean 
 
 
Ninety five percent of the recruited patients completed 6 days of follow-up after 
admission,  allowing  analysis  of  lung  function  tests  during  the  period 
immediately following the acute exacerbation. The remaining patients (3) died 
   Current 
Smokers 
(n=31) 
Ex-smokers 
 
(n=27) 
P value 
 
Age (years)*  69.1 +/- 2.2  66.1 +/- 1.84  0.83 
Male:Female  17:14  15:12  0.88 
FEV1 on admission#  0.7 
(0.23-1.63) 
0.71 
(0.25-1.0) 
0.93 
FVC on admission#       
Smoking pack years*  55.7  38.22  0.02 
Patients on inhaled Steroids  84%  85%  0.84 
Patients on long-acting β2- agonists  68%  60%  0.54 
Patients on long term oxygen therapy  4%  5%  0.83 
Past Exacerbation Rates (yr
-1) *  2.35 +/- 0.3  2.11 +/- 0.18  0.85 
MRC Score*  3.62 +/- 0.27  3.00 +/- 0.37  0.36 
SQRQ Score*  57.21 +/- 6.54  52.87 +/- 9.05  0.71 
pH on admission*  7.43 +/- 0.01  7.38 +/- 0.01  0.66 
CO2 on admission (kPa)*  5.53 +/- 0.51  6.84 +/- 0.43  0.36 
02   on admission (kPa)*  8.09 +/- 1.25  8.20 +/- 1.28  0.73 
Bicarbonate (mmol)*  26.9 +/- 1.46  29.4 +/- 1.50  0.73 
Years ex smoking*  NA  3.59 +/- 5.8  NA   85
during  admission.  If  the  patients  were  discharged  sooner  than  6  days, 
measurements  were  obtained  using  the  same  equipment  within  their  own 
homes. Only 36 of these patients could be reassessed after 42 days: 5 patients 
had died and 17 patients refused follow-up within the study. This was felt to be 
insufficient for analysis of clinical and disease mechanism outcomes. 
   
All  the  patients  received  standard  treatment  for  an  acute  exacerbation, 
consisting of a course of prednisolone (30mg OD), nebulised bronchodilators  
(salbutamol 2.5mg QDS and PRN and ipratropium 500µg QDS) and antibiotics 
(doxycycline 200mg  BD for  2  days  then  200mg  OD  for 5 days).  None  was 
admitted into the high dependency unit for non-invasive ventilation, and none 
was  intubated.  There  were  no  differences  in  treatment  received  by  the  two 
groups of patients. 
 
 
 
Length of stay in hospital and recovery of lung function 
The mean (SEM) length of stay of ex-smokers was 3·1+/- 0·12 days which was 
significantly (P<0.001) different from current smokers (5·6 +/- 0·27 days) (figure 
4.2). In current smokers FEV1 recovered significantly (P<0·05) more slowly than 
in ex-smokers. This pattern was also seen when analysing the recovery of FVC 
and IC (Figures 4.3 a, b and c). 
 
To work out the statistical analysis for the changes in lung function we used 2 
valid statistical methods. The first was to use a simple t-test (the values were 
normal distributed) which gave a p-value of P<0.01. The problem with this 
however is that because we are measuring serial data there is an increased 
chance of finding a positive result so we also used the slopes of the individual 
patients in a linear regression analysis and then compared the 2 groups. This 
also gave p-value of P<0.01.  
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Figure 4.2:  Kaplan-Meier Graph showing numbers of days patients occupied a 
hospital bed according to smoking status. Ex-smokers were discharged much 
earlier than current smokers. (p<0.001) 
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ID  Smoker  FEV 0  FEV 1  FEV 2  FEV 3  FEV 4  FEV 5  FEV 6 
1  1  2.1  1.5  1.48  1.5  1.6  1.69  1.71 
2  1  0.9  0.7  0.7  0.68  0.79  0.81  0.84 
3  1    1.63  1.57  1.59  1.68  1.71  1.74 
4  2  1.68  0.98  1.1  1.15  1.15  1.28  1.3 
5  1  0.71  0.6  0.6  0.58  0.61  0.64  0.66 
6  1  1.78  1.5  1.48  1.5  1.6  1.69  1.71 
7  2  0.93  0.88  0.81  1.1  1.12  1.17  1.17 
8  1  0.54  0.41  0.38  0.38  0.38  0.34  0.32 
9  1  0.33  0.45  0.5  0.49  0.33  0.33  0.33 
10  1  0.8  0.45  0.41  0.41  0.45  0.51  0.52 
11  1  0.99  0.83  0.83  0.83  0.9  0.83  0.91 
12  2  0.76  0.51  0.55  0.61  0.68  0.68  0.69 
13  2  1.22  0.9  0.97  1.03  1.05  1.02  1.1 
14  2  1  0.71  0.66  0.73  0.8  0.81  0.82 
15  1  0.97  0.79  0.68  0.72  0.71  0.73  0.81 
16  1  1.1  1.06  0.97  0.9  0.9  0.83  0.9 
17  2  1.29  0.9  0.93  1  1.02  1.08  1.25 
18  2  0.89  0.47  0.47  0.67  0.68  0.66  0.76 
19  1  1.28  1.13  0.88  1.1  1.1  1.15  1.15 
20  1    0.58  0.57  0.5  0.61  0.63  0.64 
21  1  0.31  0.23  0.2  0.2  0.31  0.37  0.38 
22  1  0.71  0.56  0.48  0.58  0.56  0.58  0.6 
23  2  0.7  0.26  0.38  0.38  0.41  0.47  0.49 
24  2    0.74  1  1.03  1.1  1.11   
25  1  1.13  0.7  0.72  0.61  0.72  0.61  0.81 
26  1  1.16  1.36  1.4  1.4  1.47  1.4  1.5 
27  1  0.89  0.51      0.49  0.61   
28  1    0.78  0.8  0.83  0.9  0.9  0.92 
29  2    0.34  0.41  0.47  0.48  0.5  0.5 
30  1    0.38  0.37  0.37  0.4     
31  1    0.7  0.69  0.72    0.73  0.81 
32  1  0.89  0.53  0.55  0.55  0.6  0.61   
33  2  0.99  0.81  0.88  0.88  0.9  0.92  0.94 
34  1    0.33  0.3  0.35  0.37  0.37   
35  1  0.82  0.55  0.58  0.6  0.6  0.62   
36  2    0.7  0.77  0.79  0.83  0.83   
37  2  1.01  0.8  0.9  0.92  0.94  0.96  0.99 
38  2    0.25  0.29  0.37  0.44  0.44  0.46 
39  2  0.8  0.59  0.56  0.6  0.61  0.68   
40  1  0.79  0.49  0.52  0.5  0.52  0.49  0.53 
41  2    0.49  0.53  0.54  0.56  0.58   
42  2  1.2  0.96  0.98  1.01  1.12  1.14  1.14 
43  1    0.83  0.53  0.79  0.8  0.84  0.86 
44  2  1.1  0.68  0.72  0.7  0.79  0.81   
45  2    0.51  0.54  0.6  0.6  0.69  0.74 
46  1  0.91  0.6  0.59  0.61  0.65  0.65  0.81 
47  1  1.08  0.8  0.7  0.79  0.81  0.85  0.85 
48  2  1.37  0.8  0.82  0.9  1.01  1.1  1.23 
49  1    0.57  0.59  0.58  0.59  0.61  0.62   88
50  2  0.72  0.44  0.5  0.52  0.5  0.6  0.61 
51  1  0.76  0.58  0.6  0.6  0.62  0.65   
52  2    1  1.15  1.18  1.19  1.19   
53  2    0.6  0.64  0.72  0.73  0.77  0.81 
54  2  1.1  0.91  0.93  0.97  1.02  1.03  1.04 
55  1  1.2  0.91  0.9  0.83  0.9  0.94  0.97 
56  2    0.58  0.6  0.83  0.88  0.88  0.93 
57  2  1.43  0.7  0.8  0.97  1.17  1.28  1.29 
58  2    0.71  0.93  1.15  1.2  1.26  1.27 
 
 
 
Table  4.2  Absolute  changes  in  lung  function  for  patients  1-58.  Smoking 
classification 1 – Current smoker 2 – Ex smoker. All values expressed in litres. 
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Figure 4.3a: Improvement in lung function a) FEV1 b) FVC and c) IC during an acute exacerbation since admission to hospital. Ex-smokers 
recovered much more quickly than current smokers in all parameters. 
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Detection of bacteria and viruses 
Of  the  58  samples  submitted  for  culture,  52%  grew  significant  pathological 
bacteria,  with  current smokers having  significantly (p<0.05)  more  pathogenic 
bacteria than ex-smokers (Figures 4.4 a and b). This was especially true for 
Haemophilus influenzae, which was also associated with a significantly higher 
CRP level at day 1 than any other organism detected (Figure 4.5b) (p<0·05) 
Sputum from 18 current and 13 ex-smokers were analysed for viruses. When 
pooling the data from the cell and fluid sputum phases, a total of 30 viruses 
were detected in 31 patients (figure 4.4 c and d). Some patients were infected 
with more than one species. The rate of detection tended to be higher in ex-
smokers (76·9%) than in current smokers (50%), but this was not statistically 
significant (p=0·21). There was a particularly low prevalence of S. pneumoniae 
in  this  study,  only  2  current  smokers  cultured  this  organism.  A  greater 
prevalence  of  these  bacteria  may  have  been  detected  if  we  used  PCR 
techniques. 
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Bacteria cultured from sputum
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Figure 4.4: Microbiological analysis of induced sputum in current and ex-smoking COPD patients undertaken on day 1 of admission with 
an acute exacerbation: a) bacteria species grown in culture b) differences in quantity of pathogenic bacteria grown in the sputum culture. 
Current smokers had a greater burden of bacteria. 
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Strain of virus detected
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Figure 4.4: cont.. c) virus species detected by PCR in sputum d) Quantity of virus detected. Whilst ex-smokers tested more frequently for virus 
infection this was not statistically significant 
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Bacteria isolated in culture
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Figure 4.5: a) Serum concentrations of CRP at day 1 of acute COPD exacerbation. Current smokers had  significantly higher CRP levels than 
ex-smokers.  (p<0.01)  and  b)  CRP  levels  were  highest  in  patients  in  whom  H  .influenzae  was  detected  (p<0.05).
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Measures of airway and systemic inflammation 
Analysis of  sputum cells  showed  predominant neutrophilic infiltration  with  no 
differences between the current and ex-smokers both in cell counts and degree 
of  activation  (figure  4.6).  There  was  no  difference  between  ex-  and  current 
smokers  in  granulocyte  populations  or  cell  surface  markers  of  activation  in 
blood (figure 4.7). However, current smoking was associated with significantly 
(p<0·01)  higher  CRP  concentrations  (figure  4.5a).  When  assessing  the 
proportions of CD4+ and CD8+ T cells in sputum the differences between the 
two patient groups were marked, with a predominance of CD8+ T cells in ex-
smokers  and  CD4+  T  cells  in  current  smokers  (figure  4.8),  resulting  in  a 
significant (p<0·01) difference in CD4+:CD8+ T cell ratios.  In contrast, there 
was no difference in CD4:CD8 ratios in blood. Although there was a tendency 
for  current  smokers  to  have  higher  concentrations  of  most  cytokines  on 
admission,  only  the  raised  levels  of  IL-12  in  smokers  reached  statistical 
significance (p<0·05) (figure 4.9a) 
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Figure 4.6:  The dominant cell type was the neutrophil. There were no differences 
between ex- and current smokers in the cell populations obtained by cytospins.  
NS – Neutrophil smokers NES – Neutrophil ex-smokers MS – Macrophage smokers  
MES Macrophage ex-smokers ES – Eosinophils smokers EES – Eosinophils ex-smokers 
LS – Lymphocyte smokers LES  - Lymphocyte ex-smokers 
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Figure 4.7: Granulocyte cell surface markers observed in a) sputum and b) Blood via flow cytometry.  
(ES) = Ex-smokers (S) = Current smokers. There were no statistical differences between the 2 groups in any of the activation markers. 
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Figure 4.8: Graphs showing the differences between ex-smokers and current smokers in the distribution of CD4+ and CD8+ lymphocytes in 
sputum. 
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Cytokine detected
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Figure 4.9  a. BNP levels are shown from the acute exacerbation and then at follow up six weeks later. BNP levels are higher during the acute 
exacerbation than at follow up (P<0.05). Only 3 patients reached values associated with congestive cardiac failure (dotted line), their chest x 
rays showed clear lung fields and ECG normal sinus rhythm with no acute changes. b) Luminex cytokine panel results. The only statistically 
significant cytokine difference was observed  for IL12 p70 which is associated with bacterial infections.
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Post-hoc analysis of mortality 
13 current smokers (smoking at the time of admission) and 6 ex-smokers died 
within one year of admission (figure 4.10) (p=0·053). The cause of death was 
felt not be sufficiently reliable to be included in the analysis. 
 
 
 
Figure 4.10: Kaplan-Meier graph showing the mortality over a one year period 
after being admitted with an acute exacerbation of COPD. The mortality in the 
current  smokers  was  higher  than  ex-smokers,  but  this  was  not  significant. 
(p<0.053) 
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Chapter 5 Discussion and Conclusion 
 
 
5.1 Demographics and recruitment 
The majority of the patients were recruited from the Acute Medical Unit in 
Southampton General Hospitals NHS Trust (SGH), only 5 patients were 
recruited through our Respiratory Centre which receives patients from either 
self referral or via their GP. The exclusion criteria had to be rigorous in order to 
ensure that all the patients recruited were admitted with an exacerbation of 
COPD and that no other co-morbidity or other infectious process was at the 
centre of their admission. Criticisms have often been made of papers that fail to 
make the diagnosis concrete. To this end, I have not only confirmed the 
diagnosis of COPD on history and spirometry, but also excluded pneumonia 
with a chest x-ray and other significant co-morbidities (figure 4.1) with a detailed 
history and examination supplemented by routine blood investigations and ECG 
(to exclude arrhythmias). These were combined with BNP and chest x-ray to 
confirm that congestive cardiac failure was not the cause of the dyspnoea. 
Three patients reached the levels of BNP that might be associated with heart 
failure, but were only slightly over the threshold. In these patients 
echocardiography was performed on admission and normal ventricular function 
was confirmed. The rise in BNP levels may in some part be due to 
hyperinflation.  Smoking status was also confirmed with plasma cotinine levels 
thus not relying totally on history. Finally, arterial blood gas measurements were 
made to assess the severity of the exacerbation. 
 
The 2 groups were evenly matched in all important parameters (displayed in 
Table 4.1), apart from pack years. Not surprisingly the current smokers had 
smoked significantly more cigarettes than the ex-smokers. The target of 56 
patients in the power calculation derived from the pilot study was exceeded by 
2.  
 
Overall the patients had very severe disease with a median FEV1 of 0.7 on the 
day of admission. 
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5.2 Spirometry – Improvement in Lung Function 
The micro medical hand held spirometer was ideal for use in this study, and the 
majority (95%) of the patients completed spirometry up until day 6 of their 
admission. Even though the patients were suffering with a severe exacerbation 
they were able to understand and perform most of the manoeuvres without 
difficulty.  
 
The improvement in spirometry during the AECOPD is shown in figure 4.3 a,b, 
and c.  Ex-smokers recovered much more quickly from their exacerbation than 
current smokers in all spirometric parameters. In the ex-smoking population 
recovery of lung function is shown to occur from day 1 onwards. In the current 
smoking population, recovery to even the baseline of the admission test can 
take 2 or 3 days. Even at day 6 there is a large difference between the 
populations. Thus, the results of this study confirmed what I had previously 
found in the pilot study which led to initiating this research.  
 
FEV1 was the easiest measurement to perform for the patient. When performing 
an FVC during an acute exacerbation there was great difficulty completing the 
manoeuvre in the first attempt due to coughing; however many patients found 
this therapeutic and were able to expectorate sputum following this. Once the 
patient was trained sufficiently, IC (some patients did find the manoeuvre 
difficult to understand and perform) was also well reproduced during the 3 
attempts, however improvements were seen in all 3 parameters and the most 
reproducible of the 3 was FEV1. 
 
The graphs are all quite similar apart from the larger SEM observed in the FVC 
graph which is not surprising considering the larger values obtained, and the 
greater difficulty in performing the test. 
 
The theory about why this discrepancy is seen between the 2 groups is 
discussed in the conclusion. These results support the use of FEV1 in COPD 
studies, as neither FVC nor IC contributed additional information, and are not 
as easily reproduced. The improvement in IC however does support the body of 
research postulating that a reduction in hyperinflation during an acute 
exacerbation allows the patient to breath easier from a lower resting lung 
volume. Indeed it is often the high respiratory rate from the exacerbation that   102 
causes the significant lung trapping leading to hyperinflation. Reassurance, 
rest, nursing care and pharmacotherapy (as well as NIV in the serious cases 
with type II respiratory failure and respiratory acidosis) help reduces the overall 
respiratory rate, improve bronchodilation, increase expiratory time, and thus 
allowing deflation to occur. 
 
5.3 Length of hospital stay and mortality 
The ex-smokers stayed far fewer days in hospital (mean 3.08) compared to 
current smokers (mean 5.59 days). This reduction was very significant 
(P<0.001). This correlates is in keeping with the improvements in lung function 
observed between the 2 groups. This has an obvious socioeconomic impact, 
however does not lead to a significant cost saving to primary care due to the 
changes in the tariff structure since payment by results was introduced. 
 
At one year I followed up the mortality data to see if there was a significant 
difference between the 2 groups. One year all cause mortality after the 
admission for an acute exacerbation of COPD was higher in current smokers 
than ex smokers but did not reach quite reach significance (P=0.053).  I realise 
that this is a post-hoc analysis and that the study was not powered to look at 
this end point, but the result is interesting none the less because apart from 
smoking status the 2 groups were evenly matched before the exacerbation. 
Several studies of smoking status and mortality have been published, none with 
more subjects than the recent study published by Doll in the BMJ (155) which 
showed that ex-smokers had a significantly reduced all cause mortality rate 
compared to their current smoking colleagues. It may be there are significant 
improvements in the immune defence in the ex-smokers to account for the 
discrepancies seen. This area needs to be further studied in a much larger 
prospective study. 
 
5.4 Bacteriology 
Overall the results from the bacterial cultures support current literature that 
H.influenzae is the most common bacteria pathogen isolated during acute 
exacerbations. This study, however, has shown for the first time that there is a 
large difference in the bacterial pathogen and the frequency isolated between 
current and ex-smokers. Bacterial pathogens are far more likely to be isolated 
in the current smokers than the ex-smokers (P<0.05 – graph 4.4) and 
especially H.influenzae which was isolated in 12 out of the 31 current smoking   103 
patients as opposed to only 2/27 of the ex-smokers. H.influenzae was also 
associated with a much higher CRP level at day one than any other organism 
(figure 4.4b) and contributed to a much higher CRP level overall in the current 
smoking population (figure 4.4a). As mentioned in the introduction to this thesis 
phagocytosis by alveolar macrophages of smokers has been shown to be 
accompanied by increased bactericidal activity compared with alveolar 
macrophages of non smokers. In a study of the effectiveness of alveolar 
macrophages to clear H.influenzae (132), the authors found that ex-smoker 
alveolar macrophages displayed immunologic properties that were more like 
alveolar macrophages of non smokers. This supports the theory that current 
smokers are less able to clear this very influential pathogen.  The elevated 
cytokine levels associated with H.influenzae above any other organism have 
been published (116), however there is little in the way of publications looking 
specifically at the organism isolated at the time of exacerbation and 
corresponding CRP levels; especially in patients admitted with a severe 
exacerbation. In fact in this study if a patient is admitted with an acute 
exacerbation, has a CRP level above 100, and is a current smoker then the 
organism isolated was always H.influenzae 
 
Higher levels of cytokines IL2, IL6 and IL8 were observed in patients in whom a 
bacteria was detected (P<0.05).  
 
5.5 Virology 
The detection of viruses from sputum is notoriously difficult and this study was 
no exception. Initially the detection of viruses from our experiments was poor 
until it was discovered that there was significant interference at play – see 
methods section for more details. The most commonly virus isolated in our 
population was Influenza AH3 closely followed by Rhinovius (figure 4.4 c,d), 
these findings are broadly in line with previous studies outlined in the 
introduction. The lack of detection of Rhinovirus may have been due to 
technical problems. The exacerbations in ex-smokers were caused by a virus in 
77% of cases, as opposed to 50% in current smokers, but this difference was 
not significant (P=0.21). The study was almost certainly underpowered to detect 
such a difference. Nevertheless, the results of my study suggest that the 
infectious cause of AECOPD may differ between smokers and ex-smokers, with 
bacterial agents being more frequently associated in smokers whilst viruses 
appear to play a more important role in ex-smokers. Whether and to what   104 
extent this could be linked with the observed differences in CD8+ T cells in 
smokers and ex-smokers is unclear as the specificity of CD8+ T cells has not 
been determined, but it is tempting to speculate that the CD8+ T cell population 
could contain virus-specific T cells. 
 
The difference in the microbiological insult may go some way in explaining the 
difference between the 2 groups; with current smoker exacerbations mainly due 
to bacterial pathogens (with H.influenzae the main bacterium) and ex-smokers 
mainly due to viral infections. There is certainly a large difference between 
these 2 groups in overall systemic inflammatory response denoted by CRP 
caused by H.influenzae which is a good reason why recovery may take much 
longer in the current smoker. 
   
5.6 Flow cytometry and inflammatory cell counts 
There are few papers exploring the use of flow cytometry methods in sputum 
but this is an expanding field. Flow cytometry allows us to distinguish cell types 
present in the sputum, their subtypes and also allows us to detect markers of 
cell activation. As discussed the only difference between the 2 groups in this 
study was in the T-cell CD4:CD8 ratios in sputum and in blood 
 (figure 4.8). Neutrophils, eosinophils and macrophages were observed in 
similar quantities in both groups; their markers of activation were also non 
significant (figure 4.7). However, my numbers of samples assessed by flow 
cytometry are small as I only introduced this to the study half-way through 
recruitment as validation of the technique took much longer than expected. The 
detection of low numbers of eosinophils does deserve a mention as a few 
studies have shown an increase in eosinophils during acute 
exacerbations.(141)  
 
The number of eosinophils detected by flow cytometry was similar in both 
groups and did not depend on whether the pathogen was viral or bacterial. This 
was backed up by the analysis of our slides obtained from the cytospins; these 
showed a low eosinophil level (<1%) but a large neutrophil predominance. 
There is no obvious reason for this discrepancy however the populations 
studied previously tended to be at the more mild/moderate end of the disease 
spectrum compared to the severe patients studied here. 
 
The major difference observed between the 2 groups was seen in the    105 
T-lymphocyte population with current smokers having a much higher CD4:CD8 
ratio than ex smokers. This can partly be explained by the difference in 
pathogen isolated from the patients (viral infections tend to move t-lymphocytes 
towards CD8 predominance) and also possibly by a difference in the immune 
mechanisms at play between the 2 groups. (Figures 4.8). 
 
The white cell count and neutrophil count were higher in the current smokers 
than ex-smokers; however the difference was not significant. The higher values 
in the current smokers were to be expected with bacterial infections the 
predominant infective aetiology. 
 
5.7 Cytokines 
The development of the luminex system has allowed us to investigate a whole 
spectrum of cytokines quickly and with great accuracy. I found that apart from 
TNFα and IL10 the cytokines were seen in greater quantities in the current 
smoking population. The only significant result however was seen with IL12p70 
which is significantly higher (p<0.05) in current smokers than ex smokers 
(Figure 4.11). It is possible that a properly powered study involving larger 
numbers of patients might detect significant differences. 
 
IL-12 is a heterodimeric 70 kDa glycoprotein (IL-12-p70) consisting of a 40 kDa 
subunit. It is secreted by peripheral lymphocytes after induction and is produced 
mainly by B-cells and to a lesser extent by T-cells. The most powerful inducers 
of IL-12 are bacteria and bacterial products which explains why the levels are 
higher in the current smoking population. 
 
5.8 BNP 
I found that during an acute exacerbation BNP levels were much higher 
(P<0.001) than during the stable state (figure 4.18). BNP levels in only 3/58 
patients reached levels associated with congestive cardiac failure. Importantly, 
BNP levels did not differ between the 2 patient groups, which means that I can 
exclude with confidence heart failure as an explanation for the worse clinical 
outcome in current smokers.  
 
BNP has been shown to be the best discriminatory marker to differentiate 
cardiac dyspnoea from all other cause of dyspnoea in a whole series of trials. 
With regards to ventricular function in respiratory medicine we are more   106 
interested in right heart dysfunction, and BNP has been shown to be raised in 
patients with pulmonary hypertension, cor pulmonale and pulmonary embolism. 
(93) BNP has been shown to increase in proportion to the degree of right 
ventricular dysfunction, but to a lesser degree compared to left ventricular 
dysfunction. In right ventricular dysfunction raised concentrations of BNP is a 
predictor for increased risk of death, even in cor pulmonale and primary 
pulmonary hypertension. In pulmonary embolism low BNP levels within 4 hours 
of admission are associated with an uneventful hospital admission, and may be 
useful in identifying patients for treatment in an outpatient setting. (97) 
 
What my findings add to the field is that BNP levels do not rise significantly 
above the threshold normally associated with congestive cardiac failure; even 
during an acute exacerbation of COPD, and therefore BNP is a useful 
discriminatory test in those cases when the diagnosis is in doubt. 
 
5.9 Limitations of the Study 
There at least a couple of ways in which this study could have been improved. 
The lack of baseline measurements on the subjects would have added greatly 
to the understanding in improvements in spirometric parameters during the 
study, allowing us to express these as percentage of baseline. 
 
Serial measurements of symptom improvements in these patients would have 
been helpful, and with hindsight I should have encouraged the patients to 
record their symptoms on diary cards with an analogue measurement of 
dyspnoea scores.  107 
Conclusion 
 
In the first study of its kind, we have shown that smoking status has a major 
impact on the nature of COPD exacerbations, resulting in slower recovery of 
lung function and delayed discharge, factors which are of importance to both 
patients and health resources. Current smoking was associated with a more 
significant bacterial burden, in particular H. influenzae, and higher serum CRP 
levels, suggesting that cigarette smoke alters both the local environment in the 
lungs and the systemic consequences of acute infectious exacerbations. 
   
In the UK, COPD accounts for up to 10% of all acute annual admissions,(156) 
and patients experience on average 1 to 3 exacerbations per year, the highest 
exacerbation  rate  being  related  to  low  FEV1  (157).    Exacerbations  are 
responsible for 30,000 premature deaths per year in the UK, and mortality is 
still rising, especially in the female and elderly populations. (3) Exacerbations 
also account for at least 50% of  the  treatment cost of  COPD;  these figures 
make COPD a priority disease for all acute medical services. (11, 156) 
   
There  have  been  several  studies  following  COPD  patients  during  their 
exacerbation  and  monitoring  recovery  by  measuring  FEV1.  (158,  159)  Our 
results  support  FEV1  as  an  appropriate  measurement  for  use  in  COPD 
exacerbation studies, because in our experience more sophisticated measures, 
such as IC, are not necessarily reproducible in the critically ill patients as this 
requires more effort on the patient’s part. The exacerbating patient often found 
it difficult to understand such manoeuvres and to complete. The same was true 
for FVC where patients found it difficult to reach a plateau in the time-volume 
curve due to dyspnoea. 
   
In the current study, ex-smokers demonstrated a greater improvement in FEV1 
already one day  after  being admitted, and this increased linearly during the 
admission. In  contrast,  in  current  smokers  first  improvement  was  noticeable 
only after 2 days. This finding is compounded by the hospital length of stay, 
with ex-smokers recovering much more quickly during their exacerbation than 
current  smokers,  resulting  in  a  hospital  stay  2·5  days  shorter  than  current 
smokers, which equates  to a 55%  saving in  use  of hospital beds.  This  has 
important socioeconomic implications.  
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The  finding of  major differences  in  the  microbiological  insult  suffered during 
exacerbation  in  this  study  sheds  light  on possible  reasons for why  smokers 
have a different course of exacerbation. Routine culture of sputum showed H. 
influenzae to be the predominant microbe isolated, accounting for 37% of all 
isolates. Whilst this study does not have the power to sub-analyse the clinical 
and pathological features of patients positive for H. influenzae, the fact that 12 
of a total of 30 were positive in current smokers and only 3 of 21 were positive 
in  ex-smokers  suggests  that  smoking  might  alter  the  susceptibility  to  this 
common  bacterial  strain.  The  role  of  bacteria  in  stable  COPD  and  during 
exacerbations  has  been  extensively  studied  and  H.  influenzae  has  been 
consistently  shown  to be  the  most frequently isolated bacterium. It has  also 
been  shown  to  produce  the  greatest  inflammatory  responses,  even  when 
isolated  as  a  colonising  bacterium.  (121)
,(127)  Patients  whose  airways  are 
colonised  by  H.  influenzae  in  the  stable  state  report  more  symptoms  and 
increased sputum purulence at exacerbation than those not colonized (118). 
Bacterial colonisation, a feature of COPD, especially in the more severe forms, 
is known to be more prevalent in current smokers. (160) 
   
This study has shown that current smokers have a considerably greater degree 
of systemic inflammation, as denoted by CRP serum levels, and thus adds to 
the considerable body of evidence pointing to the role of systemic inflammation 
in  COPD.(161)  Indeed,  recent  studies  have  shown  CRP  to  be  the  most 
sensitive biomarker of an exacerbation. (58)  Whether higher CRP levels in the 
current study are due to smoking or the presence of H. influenzae is unclear. 
Smokers  in  general  have  higher  serum  concentrations  of  CRP,  (162)  but 
bacterial colonisation with such bacteria as H. influenzae and Psedudomonas 
Aeruginosa  has  also been  associated  with higher  CRP levels. (127)  CRP is 
also linked to worse pulmonary function even in individuals without pulmonary 
disease. (64)   
 
The finding of differing CD4+ to CD8+ ratios in the sputum on admission seen 
when comparing ex- and current smokers is also the first observation of its kind 
and suggests significant differences in the involvement of these central cells of 
acquired immunity. Ex-smokers were found to have a predominant CD8+ T cell 
population  in  sputum,  a  finding  which  is  in  keeping  with  observations  in 
bronchial  biopsies  of  patients  with  stable  COPD.  (146)  How  this  relates  to 
smoking status is unclear. Cigarette smoking has been shown to be associated   109 
with a selective increase in CD4+ cells in peripheral blood when compared to 
non-smokers. (149, 150) The finding that viruses were more readily detected in 
ex-smokers,  albeit  not  significantly,  while  bacteria  were  more  prevalent  in 
current smokers also suggests possible differences in immune responses.  It is 
tempting  to  speculate  that  these  differences  could  explain  why  ex-smokers 
recover much more quickly than current smokers. 
   
Ever  since  the  publication of the graphs  of  Fletcher and Peto, depicting the 
relentless decline in lung function associated with smoking (163), a major effort 
has  been  directed  at  smoking  cessation.  The  findings  of  our  study  should 
provide further incentive and a strong public message to current smokers with 
COPD to quit. In addition to showing a worse immediate clinical outcome, the 
study shows a clear trend towards increased mortality and markedly increased 
costs of treatment of acute exacerbations in smokers with COPD. The current 
study  should be viewed as  a pilot study  in  respect of  the  respective  role  of 
viruses and bacteria in causing exacerbations and should provide incentive to 
elucidate the role of bacterial colonization as compared to acquisition of new 
strains of bacteria in smokers. (129) This could have implications for strategies 
to  prevent  exacerbations,  possibly  including  selection  of  patients  for 
prophylactic  antibiotic  use  which  has  recently  been  demonstrated  to  reduce 
exacerbation rates. (164) 
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Future Studies 
 
I have several studies lined up on completion of my Doctorate in Medicine. I 
have a clinical and academic position within Southampton University, The 
Biomedical Research Unit and Southampton University Hospital as clinical lead 
for COPD. I have developed an advanced community service structure with the 
help of the local Primary Care Trust and this provides an ideal opportunity to 
create a large well phenotyped population of COPD patients to help with basic 
and translational research. We initially aim to recruit a cohort of 150 patients, 50 
mild, 50 moderate and 50 severe. I then aim to see if the results from this study 
are reproduced in the moderate population and further expand the study with 
regards to cell activation and ratios using flow cytometry. I am also interested to 
see if the introduction of the intermediate services and change in service 
provision has made an impact on the COPD population in Southampton City. 
 
The underlying basic mechanisms for the differences observed in this paper 
also deserve further research and I plan to further explore the difference in the 
T-Cell populations in current and ex-smokers, and then extend this to research 
into macrophage biology. 
 
I am also very interested in looking at decline in lung function in COPD patients 
in a well phenotyped population and reproduce some of the work by Fletcher 
and Peto to confirm that the attenuation of lung function decline with cessation 
of smoking is seen within a well phenotyped population with COPD. 
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